AgroFresh Solutions, Inc. - Quarter Report: 2020 June (Form 10-Q)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2020
or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ___ to ___
Commission File Number: 001-36316
AgroFresh Solutions, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware | 46-4007249 | ||||
(State or other jurisdiction of incorporation) | (IRS Employer Identification Number) |
One Washington Square
510-530 Walnut Street, Suite 1350
Philadelphia, PA 19106
(Address of principal executive offices)
(267) 317-9139
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Common Stock, par value $0.0001 per share | AGFS | The Nasdaq Stock Market LLC | ||||||||||||
Warrants to purchase shares of Common Stock | AGFSW | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. x Yes ¨ No
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). x Yes ¨ No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer ☐ | Accelerated filer ☐ | Non-accelerated filer ☒ | Smaller reporting company ☒ | Emerging growth company ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Act). ☐ Yes x No
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
The number of shares of common stock outstanding as of July 27, 2020 was 52,875,089.
TABLE OF CONTENTS
Page | |||||||||||
2
PART I - FINANCIAL INFORMATION
AgroFresh Solutions, Inc.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
(In thousands, except share and per share data)
June 30, 2020 | December 31, 2019 | |||||||
ASSETS | ||||||||
Current Assets: | ||||||||
Cash and cash equivalents | $ | 35,619 | $ | 29,288 | ||||
Accounts receivable, net of allowance for doubtful accounts of $2,005 and $2,232, respectively | 38,418 | 68,634 | ||||||
Inventories | 25,119 | 22,621 | ||||||
Other current assets | 16,740 | 11,802 | ||||||
Total Current Assets | 115,896 | 132,345 | ||||||
Property and equipment, net | 12,890 | 13,177 | ||||||
Goodwill | 6,351 | 6,323 | ||||||
Intangible assets, net | 609,545 | 631,369 | ||||||
Deferred income tax assets | 10,564 | 10,317 | ||||||
Other assets | 12,191 | 12,161 | ||||||
TOTAL ASSETS | $ | 767,437 | $ | 805,692 | ||||
LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
Current Liabilities: | ||||||||
Accounts payable | $ | 15,182 | $ | 15,105 | ||||
Current portion of long-term debt | 4,776 | 4,675 | ||||||
Income taxes payable | 6,607 | 5,648 | ||||||
Accrued expenses and other current liabilities | 19,460 | 24,350 | ||||||
Total Current Liabilities | 46,025 | 49,778 | ||||||
Long-term debt | 397,898 | 398,064 | ||||||
Other noncurrent liabilities | 6,565 | 7,246 | ||||||
Deferred income tax liabilities | 11,677 | 16,574 | ||||||
Total liabilities | 462,165 | 471,662 | ||||||
Commitments and contingencies (see Note 20) | ||||||||
Stockholders’ Equity: | ||||||||
Common stock, par value $0.0001; 400,000,000 shares authorized, 52,875,089 and 51,839,527 shares issued and 52,213,708 and 51,178,146 outstanding at June 30, 2020 and December 31, 2019, respectively | 5 | 5 | ||||||
Preferred stock, par value $0.0001; 1 share authorized and outstanding at June 30, 2020 and December 31, 2019, respectively | — | — | ||||||
Treasury stock, par value $0.0001; 661,381 shares at June 30, 2020 and December 31, 2019, respectively | (3,885) | (3,885) | ||||||
Additional paid-in capital | 562,584 | 561,006 | ||||||
Accumulated deficit | (219,823) | (199,621) | ||||||
Accumulated other comprehensive loss | (40,831) | (31,060) | ||||||
Total AgroFresh Stockholders’ Equity | 298,050 | 326,445 | ||||||
Non-controlling interest | 7,222 | 7,585 | ||||||
Total Stockholders' Equity | 305,272 | 334,030 | ||||||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 767,437 | $ | 805,692 |
See accompanying notes to unaudited condensed consolidated financial statements.
3
AgroFresh Solutions, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(In thousands, except share and per share data)
Three Months Ended June 30, 2020 | Three Months Ended June 30, 2019 | Six Months Ended June 30, 2020 | Six Months Ended June 30, 2019 | |||||||||||
Net sales | $ | 19,982 | $ | 21,183 | $ | 53,005 | $ | 60,123 | ||||||
Cost of sales (excluding amortization, shown separately below) | 6,453 | 6,289 | 14,981 | 17,624 | ||||||||||
Gross profit | 13,529 | 14,894 | 38,024 | 42,499 | ||||||||||
Research and development expenses | 2,895 | 3,257 | 5,537 | 7,154 | ||||||||||
Selling, general and administrative expenses | 12,722 | 16,148 | 26,431 | 32,046 | ||||||||||
Amortization of intangibles | 10,936 | 11,766 | 21,893 | 23,382 | ||||||||||
Impairment of long lived assets | — | 992 | — | 992 | ||||||||||
Change in fair value of contingent consideration | — | 167 | — | 357 | ||||||||||
Grant income | (2,974) | — | (2,974) | — | ||||||||||
Operating loss | (10,050) | (17,436) | (12,863) | (21,432) | ||||||||||
Other (expense) income | (7) | (26) | 1,500 | (38) | ||||||||||
Gain (loss) on foreign currency exchange | 449 | (2,519) | 1,076 | (2,938) | ||||||||||
Interest expense, net | (6,513) | (8,670) | (13,479) | (17,415) | ||||||||||
Loss before income taxes | (16,121) | (28,651) | (23,766) | (41,823) | ||||||||||
Income taxes expense (benefit) | 630 | (6,290) | (3,201) | (6,877) | ||||||||||
Net loss including non-controlling interests | (16,751) | (22,361) | (20,565) | (34,946) | ||||||||||
Less: Net loss attributable to non-controlling interests | (197) | (92) | (363) | (58) | ||||||||||
Net loss attributable to AgroFresh Solutions, Inc | $ | (16,554) | $ | (22,269) | $ | (20,202) | $ | (34,888) | ||||||
Net loss per share: | ||||||||||||||
Basic | $ | (0.33) | $ | (0.45) | $ | (0.41) | $ | (0.70) | ||||||
Diluted | $ | (0.33) | $ | (0.45) | $ | (0.41) | $ | (0.70) | ||||||
Weighted average shares outstanding: | ||||||||||||||
Basic | 50,758,273 | 50,146,513 | 50,646,522 | 50,094,822 | ||||||||||
Diluted | 50,758,273 | 50,146,513 | 50,646,522 | 50,094,822 |
See accompanying notes to unaudited condensed consolidated financial statements.
4
AgroFresh Solutions, Inc.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(Unaudited)
(In thousands)
Three Months Ended June 30, 2020 | Three Months Ended June 30, 2019 | Six Months Ended June 30, 2020 | Six Months Ended June 30, 2019 | |||||||||||
Net loss | $ | (16,751) | $ | (22,361) | $ | (20,565) | $ | (34,946) | ||||||
Other comprehensive loss: | ||||||||||||||
Unrealized gain (loss) on hedging activity, net of tax of $(57), $—, $142 and $—, respectively | 213 | — | (533) | — | ||||||||||
Recognition of gain on hedging activity reclassified to net loss, net of tax of $78, $78, $157 and $157, respectively | (279) | (278) | (556) | (556) | ||||||||||
Foreign currency translation adjustments | 417 | 7,223 | (8,682) | 2,920 | ||||||||||
Comprehensive loss | $ | (16,400) | $ | (15,416) | $ | (30,336) | $ | (32,582) |
See accompanying notes to unaudited condensed consolidated financial statements.
5
AgroFresh Solutions, Inc.
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ EQUITY
(Unaudited)
(In thousands, except share and per share data)
Preferred Stock | Common Stock | Treasury Stock | Additional Paid-in Capital | Accumulated Deficit | Accumulated Other Comprehensive Loss | Non-Controlling Interest | Total Stockholders’ Equity | |||||||||||||||||||||||||
Shares | Amount | Shares | Amount | Amount | ||||||||||||||||||||||||||||
Balances, December 31, 2019 | 1 | $ | — | 51,839,527 | $ | 5 | $ | (3,885) | $ | 561,006 | $ | (199,621) | $ | (31,060) | $ | 7,585 | $ | 334,030 | ||||||||||||||
Stock-based compensation | — | — | — | — | — | 1,601 | — | — | — | 1,601 | ||||||||||||||||||||||
Issuance of stock, net of forfeitures | — | — | 991,361 | — | — | — | — | — | — | — | ||||||||||||||||||||||
Shares withheld for taxes | — | — | (40,168) | — | — | (220) | — | — | — | (220) | ||||||||||||||||||||||
Issuance of common stock under employee stock purchase plan | — | — | 84,369 | — | — | 197 | — | — | — | 197 | ||||||||||||||||||||||
Comprehensive loss | — | — | — | — | — | — | (20,202) | (9,771) | (363) | (30,336) | ||||||||||||||||||||||
Balances, June 30, 2020 | 1 | $ | — | 52,875,089 | $ | 5 | $ | (3,885) | $ | 562,584 | $ | (219,823) | $ | (40,831) | $ | 7,222 | $ | 305,272 |
Preferred Stock | Common Stock | Treasury Stock | Additional Paid-in Capital | Accumulated Deficit | Accumulated Other Comprehensive Loss | Non-Controlling Interest | Total Stockholders’ Equity | |||||||||||||||||||||||||
Shares | Amount | Shares | Amount | Amount | ||||||||||||||||||||||||||||
Balances, March 31, 2020 | 1 | $ | — | 51,835,988 | 5 | (3,885) | $ | 561,483 | $ | (203,269) | $ | (41,182) | $ | 7,419 | $ | 320,571 | ||||||||||||||||
Stock-based compensation | — | — | — | — | — | 958 | — | — | — | 958 | ||||||||||||||||||||||
Issuance of stock, net of forfeitures | — | — | 964,532 | — | — | — | — | — | — | — | ||||||||||||||||||||||
Shares withheld for taxes | — | — | (9,800) | — | — | (54) | — | — | — | (54) | ||||||||||||||||||||||
Issuance of common stock under employee stock purchase plan | — | — | 84,369 | — | — | 197 | — | — | — | 197 | ||||||||||||||||||||||
Comprehensive (loss) gain | — | — | — | — | — | — | (16,554) | 351 | (197) | (16,400) | ||||||||||||||||||||||
Balances, June 30, 2020 | 1 | $ | — | 52,875,089 | 5 | (3,885) | $ | 562,584 | $ | (219,823) | $ | (40,831) | $ | 7,222 | $ | 305,272 |
Preferred Stock | Common Stock | Treasury Stock | Additional Paid-in Capital | Accumulated Deficit | Accumulated Other Comprehensive Loss | Non-Controlling Interest | Total Stockholders’ Equity | |||||||||||||||||||||||||
Shares | Amount | Shares | Amount | Amount | ||||||||||||||||||||||||||||
Balances, December 31, 2018 | 1 | $ | — | 51,071,573 | $ | 5 | $ | (3,885) | $ | 535,819 | $ | (138,789) | $ | (28,837) | $ | 8,263 | $ | 372,576 | ||||||||||||||
Stock-based compensation | — | — | — | — | — | 1,440 | — | — | — | 1,440 | ||||||||||||||||||||||
Issuance of stock, net of forfeitures | — | — | 549,197 | — | — | — | — | — | — | — | ||||||||||||||||||||||
Comprehensive (loss) gain | — | — | — | — | — | — | (34,888) | 2,364 | (58) | (32,582) | ||||||||||||||||||||||
Balances, June 30, 2019 | 1 | $ | — | 51,620,770 | $ | 5 | $ | (3,885) | $ | 537,259 | $ | (173,677) | $ | (26,473) | $ | 8,205 | $ | 341,434 |
Preferred Stock | Common Stock | Treasury Stock | Additional Paid-in Capital | Accumulated Deficit | Accumulated Other Comprehensive Loss | Non-Controlling Interest | Total Stockholders’ Equity | |||||||||||||||||||||||||
Shares | Amount | Shares | Amount | Amount | ||||||||||||||||||||||||||||
Balances, March 31, 2019 | 1 | $ | — | 51,425,734 | $ | 5 | $ | (3,885) | $ | 536,407 | $ | (151,408) | $ | (33,418) | $ | 8,297 | $ | 355,998 | ||||||||||||||
Stock-based compensation | — | — | — | — | — | 852 | — | — | — | 852 | ||||||||||||||||||||||
Forfeiture of stock, net of issuances | — | — | 195,036 | — | — | — | — | — | — | — | ||||||||||||||||||||||
Comprehensive (loss) gain | — | — | — | — | — | — | (22,269) | 6,945 | (92) | (15,416) | ||||||||||||||||||||||
Balances, June 30, 2019 | 1 | $ | — | 51,620,770 | $ | 5 | $ | (3,885) | $ | 537,259 | $ | (173,677) | $ | (26,473) | $ | 8,205 | $ | 341,434 |
See accompanying notes to unaudited condensed consolidated financial statements.
6
AgroFresh Solutions, Inc.
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(Unaudited)
(in thousands) | Six Months Ended June 30, 2020 | Six Months Ended June 30, 2019 | ||||||
Cash flows from operating activities: | ||||||||
Net loss | $ | (20,565) | $ | (34,946) | ||||
Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
Depreciation and amortization | 23,145 | 24,336 | ||||||
(Benefit) provision for bad debts | (81) | 309 | ||||||
Stock-based compensation | 1,600 | 1,440 | ||||||
Impairment of intangible assets | — | 992 | ||||||
Amortization of deferred financing costs | 1,163 | 1,409 | ||||||
Interest income on interest rate swap | (713) | (713) | ||||||
Accretion of contingent consideration | — | 1,772 | ||||||
Change in fair value of contingent consideration | — | 357 | ||||||
Deferred income taxes | (5,668) | (8,203) | ||||||
Loss on sales of property | 126 | 31 | ||||||
Changes in operating assets and liabilities: | ||||||||
Accounts receivable | 24,901 | 21,393 | ||||||
Inventories | (3,957) | (1,138) | ||||||
Prepaid expenses and other current assets | (5,942) | (832) | ||||||
Accounts payable | 83 | 4,791 | ||||||
Accrued expenses and other liabilities | (4,545) | (3,739) | ||||||
Income taxes payable | 1,669 | (457) | ||||||
Other assets and liabilities | (2,061) | (675) | ||||||
Net cash provided by operating activities | 9,155 | 6,127 | ||||||
Cash flows from investing activities: | ||||||||
Cash paid for property and equipment | (905) | (3,269) | ||||||
Other investments | — | (250) | ||||||
Net cash used in investing activities | (905) | (3,519) | ||||||
Cash flows from financing activities: | ||||||||
Proceeds from long-term debt | 1,395 | — | ||||||
Repayment of long-term debt | (2,683) | (2,805) | ||||||
Proceeds from issuance of stock under employee stock purchase plan | 197 | — | ||||||
Net cash used in financing activities | (1,091) | (2,805) | ||||||
Effect of exchange rate changes on cash and cash equivalents and restricted cash | (1,357) | 1,737 | ||||||
Net increase in cash and cash equivalents and restricted cash | 5,802 | 1,540 | ||||||
Cash and cash equivalents and restricted cash, beginning of period | 29,817 | 34,852 | ||||||
Cash and cash equivalents, end of period | $ | 35,619 | $ | 36,392 | ||||
Supplemental disclosures of cash flow information: | ||||||||
Cash paid for: | ||||||||
Cash paid for interest | $ | 12,726 | $ | 10,255 | ||||
Cash paid for income taxes | $ | 2,345 | $ | 2,230 | ||||
Supplemental schedule of non-cash investing and financing activities: | ||||||||
Accrued purchases of property and equipment | $ | 419 | $ | 52 |
See accompanying notes to unaudited condensed consolidated financial statements.
7
AgroFresh Solutions, Inc.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1. Description of Business
AgroFresh Solutions, Inc. (the “Company”) is a global leader in delivering innovative food preservation and waste prevention solutions for fresh produce. The Company is empowering the food industry with a range of integrated solutions designed to help growers, packers and retailers improve produce freshness and quality while preventing waste. The Company has an extensive portfolio of solutions to extend freshness across the produce supply chain from near-harvest up to the point-of-sale. These include HarvistaTM for near-harvest optimization and the SmartFreshTM Quality System, the Company's flagship post-harvest freshness solution. Additional post-harvest freshness solutions include fungicides that can be applied to meet various customer operational requirements in both foggable (ActiMist™) and liquid (ActiSeal™) delivery options. The Company has a controlling interest in Tecnidex Fruit Protection, S.A. (“Tecnidex”), a leading regional provider of post-harvest fungicides, waxes, disinfectants and packinghouse equipment for the citrus market. Beyond apples, SmartFresh technology can provide ready-to-eat freshness for other fruits and vegetables including avocados, bananas, melons, tomatoes, broccoli and mangos. Additionally, LandSpringTM eases transplant shock for higher potential yields. RipeLock is the Company's modified atmosphere packaging technology for fruits and vegetables. The Company has key products registered in over 50 countries and supports customers with over 25,000 storage rooms globally.
The end-markets that the Company serves are seasonal and are generally aligned with the seasonal growing patterns of the Company’s customers. For those customers growing, harvesting or storing apples and pears, the Company’s core crops, the peak season in the southern hemisphere is the first and second quarters of each year, while the peak season in the northern hemisphere is the third and fourth quarters of each year. Within each half-year period (i.e., January through June for the southern hemisphere, and July through December for the northern hemisphere) the growing season has historically occurred during both quarters. A variety of factors, including weather and fruit quality, may affect the timing of the growing, harvesting and storing patterns of the Company’s customers and therefore shift consumption of the Company’s services and products between the first and second quarters primarily in the southern hemisphere or between the third and fourth quarters primarily in the northern hemisphere.
2. Basis of Presentation and Summary of Significant Accounting Policies
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information and in accordance with the rules and regulations of the Securities and Exchange Commission. These financial statements include all adjustments that are necessary for a fair presentation of the Company's condensed consolidated results of operations, financial condition and cash flows for the periods shown, including normal, recurring accruals and other items. The condensed consolidated results of operations for the interim periods presented are not necessarily indicative of results for the full year. For additional information, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes included in the Company’s Annual Report filed on Form 10-K for the year ended December 31, 2019.
COVID-19
In March 2020, the World Health Organization characterized the coronavirus ("COVID-19") a pandemic, and the President of the United States declared the COVID-19 outbreak a national emergency. The rapid spread of the pandemic and the continuously evolving responses to combat it have had an increasingly negative impact on the global economy. For the three months ended June 30, 2020, the Company did not experience significant disruptions to operations or supply chains and results have not been materially impacted. However, there were numerous obstacles presented and some localized financial impacts of the pandemic, including the weakening of foreign currencies. While the Company is following the requirements of governmental authorities and taking additional preventative and protective measures to ensure the safety of its workforce, including implementing remote working arrangements and varying procedures for essential workforce, the Company cannot be certain there will not be any incidents across its global operations that may cause service interruptions. The rapid development and fluidity of this situation precludes any prediction as to the ultimate material adverse impact of the coronavirus outbreak, although the Company operates in an industry that thus far has not been as severely impacted as others. Nevertheless, the outbreak presents some uncertainty and risk with respect to the Company and its performance and financial results.
Adoption of Highly Inflationary Accounting in Argentina
GAAP requires the use of highly inflationary accounting for countries whose cumulative three-year inflation rate exceeds 100 percent. The Company closely monitors the inflation data and currency volatility in Argentina, where there are multiple data sources for measuring and reporting inflation. In the second quarter of 2018, the Argentine peso rapidly devalued relative to the U.S. dollar, which along with increased inflation, indicated that the three-year cumulative inflation rate in that country exceeded
8
100 percent as of June 30, 2018. As a result, the Company adopted highly inflationary accounting as of July 1, 2018 for its subsidiary in Argentina. Under highly inflationary accounting, the functional currency of the Company's subsidiary in Argentina became the U.S. dollar, and its income statement and balance sheet are measured in U.S. dollars using both current and historical rates of exchange. The effect of changes in exchange rates on Argentine peso-denominated monetary assets and liabilities are reflected in earnings. As the three-year cumulative inflation rate exceeded 100 percent as of June 30, 2020, there is no change to highly inflationary accounting. As of June 30, 2020, the Company’s subsidiary in Argentina had a net asset position of $3.9 million. Net sales attributable to Argentina were approximately 11% of the Company’s consolidated net sales for each of the six months ended June 30, 2020 and 2019.
Disaggregation of Revenue
The Company disaggregates revenue from contracts with customers into geographic region, product and timing of transfer of goods and services. The Company determined that disaggregating revenue into these categories achieves the disclosure objective of depicting how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.
Revenues for the three months ended June 30, 2020
(in thousands) | |||||||||||||||||
Region | North America (1) | EMEA (2) | Latin America (3) | Asia Pacific (4) | Total Revenues | ||||||||||||
Product | |||||||||||||||||
1-MCP based | $ | 1,581 | $ | 2,997 | $ | 5,790 | $ | 5,558 | $ | 15,926 | |||||||
Fungicides, waxes, coatings and disinfectants | — | 2,766 | 581 | — | 3,347 | ||||||||||||
Other* | 90 | 146 | 373 | 100 | 709 | ||||||||||||
$ | 1,671 | $ | 5,909 | $ | 6,744 | $ | 5,658 | $ | 19,982 | ||||||||
Pattern of Revenue Recognition | |||||||||||||||||
Products transferred at a point in time | $ | 1,579 | $ | 5,763 | $ | 6,479 | $ | 5,558 | $ | 19,379 | |||||||
Services transferred over time | 92 | 146 | 265 | 100 | 603 | ||||||||||||
$ | 1,671 | $ | 5,909 | $ | 6,744 | $ | 5,658 | $ | 19,982 |
Revenues for the three months ended June 30, 2019
(in thousands) | |||||||||||||||||
Region | North America (1) | EMEA (2) | Latin America (3) | Asia Pacific (4) | Total Revenues | ||||||||||||
Product | |||||||||||||||||
1-MCP based | $ | 1,191 | $ | 3,412 | $ | 6,385 | $ | 5,300 | $ | 16,288 | |||||||
Fungicides, waxes, coatings and disinfectants | — | 3,621 | 695 | — | 4,316 | ||||||||||||
Other* | 177 | 224 | 103 | 75 | 579 | ||||||||||||
$ | 1,368 | $ | 7,257 | $ | 7,183 | $ | 5,375 | $ | 21,183 | ||||||||
Pattern of Revenue Recognition | |||||||||||||||||
Products transferred at a point in time | $ | 1,286 | $ | 7,062 | $ | 7,140 | $ | 5,314 | $ | 20,802 | |||||||
Services transferred over time | 82 | 195 | 43 | 61 | 381 | ||||||||||||
$ | 1,368 | $ | 7,257 | $ | 7,183 | $ | 5,375 | $ | 21,183 |
9
Revenues for the six months ended June 30, 2020
(in thousands) | |||||||||||||||||
Region | North America (1) | EMEA (2) | Latin America (3) | Asia Pacific (4) | Total Revenues | ||||||||||||
Product | |||||||||||||||||
1-MCP based | $ | 2,142 | $ | 8,317 | $ | 22,372 | $ | 10,373 | $ | 43,204 | |||||||
Fungicides, waxes, coatings and disinfectants | — | 6,639 | 1,175 | — | 7,814 | ||||||||||||
Other* | 532 | 585 | 728 | 142 | 1,987 | ||||||||||||
$ | 2,674 | $ | 15,541 | $ | 24,275 | $ | 10,515 | $ | 53,005 | ||||||||
Pattern of Revenue Recognition | |||||||||||||||||
Products transferred at a point in time | $ | 2,160 | $ | 14,966 | $ | 23,918 | $ | 10,373 | $ | 51,417 | |||||||
Services transferred over time | 514 | 575 | 357 | 142 | 1,588 | ||||||||||||
$ | 2,674 | $ | 15,541 | $ | 24,275 | $ | 10,515 | $ | 53,005 |
Revenues for the six months ended June 30, 2019
(in thousands) | |||||||||||||||||
Region | North America (1) | EMEA (2) | Latin America (3) | Asia Pacific (4) | Total Revenues | ||||||||||||
Product | |||||||||||||||||
1-MCP based | $ | 3,358 | $ | 9,587 | $ | 25,824 | $ | 9,620 | $ | 48,389 | |||||||
Fungicides, waxes, coatings and disinfectants | — | 8,508 | 1,260 | — | 9,768 | ||||||||||||
Other* | 735 | 842 | 273 | 116 | 1,966 | ||||||||||||
$ | 4,093 | $ | 18,937 | $ | 27,357 | $ | 9,736 | $ | 60,123 | ||||||||
Pattern of Revenue Recognition | |||||||||||||||||
Products transferred at a point in time | $ | 3,576 | $ | 18,136 | $ | 27,284 | $ | 9,642 | $ | 58,638 | |||||||
Services transferred over time | 517 | 801 | 73 | 94 | 1,485 | ||||||||||||
$ | 4,093 | $ | 18,937 | $ | 27,357 | $ | 9,736 | $ | 60,123 |
*Other includes FreshCloud, technical services and sales-type leases related to Tecnidex.
———————————————————————————————————
(1) North America includes the United States and Canada.
(2) EMEA includes Europe, the Middle East and Africa.
(3) Latin America includes Argentina, Brazil, Chile, Costa Rica, Colombia, Dominican Republic, Ecuador, Guatemala, Mexico, Peru and Uruguay.
(4) Asia Pacific includes Australia, China, India, Japan, New Zealand, the Philippines, South Korea, Taiwan and Thailand.
Contract Assets and Liabilities
ASC 606 requires an entity to present a revenue contract as a contract asset when the entity performs its obligations under the contract by transferring goods or services to a customer before the customer pays consideration or before payment is due. ASC 606 also requires an entity to present a revenue contract as a contract liability in instances when a customer pays consideration, or an entity has a right to an amount of consideration that is unconditional (e.g., receivable), before the entity transfers a good or service to the customer. The following table presents changes in the Company’s contract assets and liabilities during the six months ended June 30, 2020 and the year ended December 31, 2019:
10
(in thousands) | Balance at January 1, 2020 | Additions | Deductions | Balance at June 30, 2020 | ||||||||||
Contract assets: | ||||||||||||||
Unbilled revenue | $ | 1,666 | 4,090 | (3,976) | $ | 1,780 | ||||||||
Contract liabilities: | ||||||||||||||
Deferred revenue | $ | 1,175 | 3,164 | (3,466) | $ | 873 |
(in thousands) | Balance at January 1, 2019 | Additions | Deductions | Balance at December 31, 2019 | ||||||||||
Contract assets: | ||||||||||||||
Unbilled revenue | $ | 1,956 | 10,029 | (10,319) | $ | 1,666 | ||||||||
Contract liabilities: | ||||||||||||||
Deferred revenue | $ | 1,280 | 3,032 | (3,137) | $ | 1,175 |
The Company recognizes contract assets in the form of unbilled revenue in instances where services are performed by the Company but not billed by period end. The Company recognizes contract liabilities in the form of deferred revenue in instances where a customer pays in advance for future services to be performed by the Company. The Company generally receives payments from its customers based on standard terms and conditions. No significant changes or impairment losses occurred to contract balances during the six months ended June 30, 2020. Amounts reclassified from unbilled revenue to accounts receivable for the six months ended June 30, 2020 and for the year ended December 31, 2019 were $4.0 million and $10.3 million, respectively. Amounts reclassified from deferred revenue to revenue for the six months ended June 30, 2020 and for the year ended December 31, 2019 were $3.5 million and $3.1 million, respectively.
Recently Issued Accounting Standards and Pronouncements
In January 2017, the Financial Accounting Standards Board ("FASB") issued ASU No. 2017-04, "Intangibles - Goodwill and Other", which simplifies the test for goodwill impairment. The guidance was effective for the Company beginning in the first quarter of fiscal year 2020. The Company adopted this standard on January 1, 2020. The adoption of this standard did not have a material impact on the condensed consolidated financial statements of the Company.
In June 2016, the FASB issued ASU 2016-13, “Measurement of Credit Losses on Financial Instruments”, which introduces a new
current expense credit loss model to measure impairment on certain types of financial instruments. This update requires an entity to use a forward-looking expected credit loss model for accounts receivable, loans, and other financial instruments. In addition, the FASB issued various amendments during 2018 and 2019 to clarify the provisions of ASU 2016-13. The standard was effective for fiscal years beginning January 1, 2020, including interim periods. The Company adopted this standard on January 1, 2020. The adoption of this standard did not have a material impact on the financial statements of the Company.
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement, which is part of the FASB disclosure framework project to improve the effectiveness of disclosures in the notes to the financial statements. The amendments in the new guidance remove, modify and add
certain disclosure requirements related to fair value measurements covered in Topic 820. The new standard was effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The Company adopted this standard on January 1, 2020. The adoption of this standard did not have a material impact on the notes to condensed consolidated financial statements of the Company.
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments simplify the accounting for income taxes by removing certain exceptions to the general principles of Topic 740, "Income Taxes" and also improve consistent application by clarifying and amending existing guidance. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020. Early adoption is permitted, with the amendments to be applied on a retrospective, modified retrospective or prospective basis, depending on the specific amendment. The Company is currently evaluating the impact of adopting this guidance.
In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting. The amendments provide optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments are intended to ease the potential burden in accounting for, or recognizing the effects of, reference rate
11
reform on financial reporting. The new standard is effective on a date selected by the Company between March 12, 2020 and December 31, 2022. The Company is currently evaluating the impact of adopting this guidance.
3. Business Combinations and Asset Acquisition
Business Combination with Dow
On July 31, 2015 (the "Closing Date"), the Company consummated a business combination (the “Business Combination”) pursuant to the Stock Purchase Agreement, dated April 30, 2015 (the “Purchase Agreement”), by and between the Company and The Dow Chemical Company ("Dow") providing for the acquisition by the Company of the AgroFresh business from Dow, resulting in AgroFresh Inc. becoming a wholly-owned, indirect subsidiary of the Company. Pursuant to the Purchase Agreement, the Company paid the following consideration to Rohm and Haas Company (“R&H”), a subsidiary of Dow: (i) 17.5 million shares of common stock and (ii) $635 million in cash.
Pursuant to a Tax Receivables Agreement among the Company, Dow, R&H and AgroFresh Inc. entered into in connection with the consummation of the Business Combination, as amended on April 4, 2017 (as so amended, the “Tax Receivables Agreement”), the Company was required to pay to Dow 50% of the annual tax savings, if any, in U.S. federal, state and local income tax or franchise tax that the Company actually realized as a result of the increase in tax basis of the AgroFresh assets resulting from a Section 338(h)(10) election that the Company and Dow made in connection with the Business Combination. In December 2019, the Tax Receivables Agreement was terminated, and the Company paid to Dow an aggregate of $16 million in settlement of all past and estimated future liabilities that would have been owed under the Tax Receivables Agreement. Based on this termination, the Company recorded a reduction of liabilities of $27.9 million. This reduction, net of deferred income taxes of $5.9 million, has been recorded to additional paid-in capital since the Tax Receivable Agreement was with a related party and is treated as a capital transaction.
Acquisition of Tecnidex
On November 7, 2017, the Company entered into a definitive agreement to acquire a controlling interest in Tecnidex. The transaction was closed on December 1, 2017. Tecnidex is a leading regional provider of post-harvest fungicides, waxes, coatings, and disinfectants for the citrus market, with clients in 18 countries. For over 35 years, Tecnidex has been helping fruit and vegetable producers offer clean, safe and high-quality products to their regional clients. The acquisition was accounted for as a purchase in accordance with ASC 805, Business Combination.
At the effective date of the acquisition, the Company agreed to pay holders of Tecnidex an estimated $25.0 million in cash for 75% of the outstanding capital stock, of which $20.0 million was paid on December 1, 2017. In 2018, the purchase price was finalized as $22.3 million after giving effect to working capital, net debt and other adjustments. The remaining $2.3 million was paid during 2018.
In accordance with the acquisition method of accounting, the Company has allocated the purchase price to the estimated fair values of the identifiable assets acquired and liabilities assumed, with any excess allocated to goodwill. The preliminary assessment of fair value of the contingent consideration payments on the acquisition date was approximately $0.7 million and was estimated by applying a probability-based income approach utilizing an appropriate discount rate. This estimation was based on significant inputs that are not observable in the market, referred to as Level 3 inputs. During the year ended December 31, 2019 there was a final adjustment made to consideration payable to holders of Tecnidex which resulted in a fair value adjustment of $0.4 million.
4. Related Party Transactions
The Company is a party to an ongoing transition services agreement with Dow, a related party. The Company incurred expenses for such transition services for the six months ended June 30, 2020 and 2019 of $0.04 million and $0.03 million, respectively. There were no outstanding amounts payable as of June 30, 2020 and 2019.
On June 13, 2020, in connection with the execution of the Investment Agreement (as defined in Note 15- Stockholders’ Equity), the Company, PSP AGFS Holdings, L.P. (the “Investor”) and R&H entered into a side agreement, pursuant to which the parties agreed that if the Investor or its affiliates has the right to designate at least 50% of the total directors on the Company’s board of directors pursuant to the Investment Agreement, so long as R&H or its affiliates beneficially owns at least 20% of the Company’s outstanding common stock (on a fully diluted, “as converted” basis), the Company and the board of directors will increase the size of the board of directors by one member and the board will elect a designee selected by R&H to fill the newly-created vacancy.
12
Such right is in addition to any right that R&H has to appoint a member of the board pursuant to its ownership of the Company’s Series A preferred stock (see Note 15- Stockholders’ Equity).
Refer to Note 3 - Business Combinations and Asset Acquisition regarding the contingent consideration owed to Dow as part of the Business Combination, as well as certain other agreements entered into in connection with the Business Combination, including the termination of the Tax Receivables Agreement in 2019.
During 2016, the Company made a minority investment in RipeLocker, LLC ("RipeLocker"), a company led by George Lobisser, a director of the Company. In February 2019, the Company made a further minority investment in RipeLocker. For the six months ended June 30, 2020, there were no material amounts paid and as of June 30, 2020, there were no material amounts owed to RipeLocker or Mr. Lobisser.
5. Inventories
Inventories at June 30, 2020 and December 31, 2019 consisted of the following:
(in thousands) | June 30, 2020 | December 31, 2019 | ||||||
Raw material | $ | 2,969 | $ | 3,401 | ||||
Work-in-process | 7,616 | 7,278 | ||||||
Finished goods | 13,310 | 10,974 | ||||||
Supplies | 1,224 | 968 | ||||||
Total inventories | $ | 25,119 | $ | 22,621 |
6. Other Current Assets
The Company's other current assets at June 30, 2020 and December 31, 2019 consisted of the following:
(in thousands) | June 30, 2020 | December 31, 2019 | ||||||
VAT receivable | $ | 7,358 | $ | 4,925 | ||||
Prepaid income tax asset | 6,222 | 3,616 | ||||||
Prepaid and other current assets | 3,160 | 3,261 | ||||||
Total other current assets | $ | 16,740 | $ | 11,802 |
7. Property and Equipment
Property and equipment at June 30, 2020 and December 31, 2019 consisted of the following:
(in thousands, except for useful life data) | Useful life (years) | June 30, 2020 | December 31, 2019 | ||||||||
Buildings and leasehold improvements | 7-20 | $ | 6,839 | $ | 6,508 | ||||||
Machinery & equipment | 1-12 | 11,014 | 10,954 | ||||||||
Furniture | 1-12 | 2,889 | 2,681 | ||||||||
Construction in progress | 1,251 | 902 | |||||||||
21,993 | 21,045 | ||||||||||
Less: accumulated depreciation | (9,103) | (7,868) | |||||||||
Total property and equipment, net | $ | 12,890 | $ | 13,177 |
Depreciation expense was $0.6 million and $0.5 million for the three months ended June 30, 2020 and 2019, respectively, and $1.3 million and $1.0 million for the six months ended June 30, 2020 and 2019, respectively. Depreciation expense is recorded in cost of sales, selling, general and administrative expense and research and development expense in the condensed consolidated statements of operations.
8. Goodwill and Intangible Assets
Changes in the carrying amount of goodwill for the six months ended June 30, 2020 and the year ended December 31, 2019 were as follows:
13
(in thousands) | June 30, 2020 | December 31, 2019 | ||||||
Beginning balance | $ | 6,323 | $ | 6,670 | ||||
Foreign currency translation | 28 | (347) | ||||||
Ending balance | $ | 6,351 | $ | 6,323 |
The Company’s intangible assets at June 30, 2020 and December 31, 2019 consisted of the following:
June 30, 2020 | December 31, 2019 | |||||||||||||||||||||||||
(in thousands) | Gross Carrying Amount | Accumulated Amortization | Impairment | Net | Gross Carrying Amount | Accumulated Amortization | Impairment | Net | ||||||||||||||||||
Other intangible assets: | ||||||||||||||||||||||||||
Developed technology | $ | 757,866 | $ | (225,134) | $ | — | $ | 532,732 | $ | 758,760 | $ | (206,998) | $ | — | $ | 551,762 | ||||||||||
In-process research and development | 39,000 | (8,306) | — | 30,694 | 39,000 | (7,222) | — | 31,778 | ||||||||||||||||||
Trade name | 27,011 | — | — | 27,011 | 27,200 | — | 27,200 | |||||||||||||||||||
Service provider network | 2,000 | — | — | 2,000 | 2,000 | — | — | 2,000 | ||||||||||||||||||
Customer relationships | 18,153 | (3,109) | — | 15,044 | 18,058 | (2,993) | — | 15,065 | ||||||||||||||||||
Software | 9,757 | (7,726) | — | 2,031 | 9,861 | (5,347) | (992) | 3,522 | ||||||||||||||||||
Other | 100 | (67) | — | 33 | 100 | (58) | — | 42 | ||||||||||||||||||
Total intangible assets | $ | 853,887 | $ | (244,342) | $ | — | $ | 609,545 | $ | 854,979 | $ | (222,618) | $ | (992) | $ | 631,369 |
During 2019, the Company recognized an impairment charge of $1.0 million associated with Verigo software following a partnership agreement with a new technology provider. During the Company's annual impairment testing conducted for the year ended December 31, 2019, the Company accelerated the amortization of Ripelock developed technology based on the Company's remaining expected useful life of the technology. This resulted in an increase to amortization expense of $34.0 million.
At June 30, 2020, the weighted-average amortization periods remaining for developed technology, in-process R&D, customer relationships, software and other was 15.0, 14.3, 12.4, 1.1, and 2.0 years, respectively, and the weighted-average amortization period remaining for these finite-lived intangible assets was 14.8 years.
Estimated annual amortization expense for finite-lived intangible assets subsequent to June 30, 2020 is as follows:
(in thousands) | Amount | ||||
2020 (remaining) | $ | 21,665 | |||
2021 | 41,649 | ||||
2022 | 40,820 | ||||
2023 | 40,720 | ||||
2024 | 40,720 | ||||
Thereafter | 394,960 | ||||
Total | $ | 580,534 |
Amortization expense for intangible assets was $10.9 million and $11.8 million for the three months ended June 30, 2020 and 2019, respectively, and $21.9 million and $23.4 million for the six months ended June 30, 2020 and 2019, respectively.
9. Other Assets
The Company’s other assets at June 30, 2020 and December 31, 2019 consisted of the following:
(in thousands) | June 30, 2020 | December 31, 2019 | ||||||
Right-of-use asset | $ | 6,506 | $ | 6,599 | ||||
Long term sales-type lease receivable | 2,116 | 2,501 | ||||||
Other long term receivable | 3,569 | 3,061 | ||||||
Total other assets | $ | 12,191 | $ | 12,161 |
14
10. Accrued and Other Current Liabilities
The Company’s accrued and other current liabilities at June 30, 2020 and December 31, 2019 consisted of the following:
(in thousands) | June 30, 2020 | December 31, 2019 | ||||||
Accrued compensation and benefits | $ | 6,215 | $ | 7,307 | ||||
Accrued taxes | 4,038 | 3,017 | ||||||
Lease liability | 1,565 | 1,493 | ||||||
Accrued rebates payable | 616 | 1,377 | ||||||
Insurance premium financing payable | — | 1,000 | ||||||
Severance | 55 | 444 | ||||||
Deferred revenue | 873 | 1,175 | ||||||
Accrued interest | 84 | 71 | ||||||
Interest rate swap | 579 | — | ||||||
Other | 5,435 | 8,466 | ||||||
Total accrued and other current liabilities | $ | 19,460 | $ | 24,350 |
Other current liabilities include primarily professional services, litigation and research and development accruals.
11. Debt
The Company’s debt, net of unamortized deferred issuance costs, at June 30, 2020 and December 31, 2019 consisted of the following:
(in thousands) | June 30, 2020 | December 31, 2019 | ||||||
Total Term Loan outstanding | $ | 403,750 | $ | 405,875 | ||||
Unamortized deferred issuance costs | (2,700) | (3,886) | ||||||
Tecnidex loan outstanding | 1,624 | 750 | ||||||
Less: Amounts due within one year | 4,776 | 4,675 | ||||||
Total long-term debt due after one year | $ | 397,898 | $ | 398,064 |
On March 23, 2020, Tecnidex entered into a €1.0 million loan agreement with Banco Santander, S.A., which provides funding through March 2023 at a 1.5% interest rate.
At June 30, 2020, the Company evaluated the amount recorded under the Term Loan (defined below) and determined that the fair value was approximately $391.6 million. The fair value of the debt is based on quoted inactive market prices and is therefore classified as Level 2 within the valuation hierarchy.
The Term Loan is presented net of deferred issuance costs, which are amortized using the effective interest method over the term of the Term Loan. Gross deferred issuance costs at the inception of the Term Loan were $12.9 million and as of June 30, 2020 there were $2.7 million of unamortized deferred issuance costs.
Scheduled principal repayments of debt subsequent to June 30, 2020 are as follows:
(in thousands) | Amount | ||||
2020 (remaining) | $ | 2,431 | |||
2021 | 402,171 | ||||
2022 | 507 | ||||
2023 | 265 | ||||
Total | $ | 405,374 |
15
Credit Facility
On July 31, 2015, in connection with the consummation of the Business Combination, AgroFresh Inc. as the borrower and its parent, AF Solutions Holdings LLC (“AF Solutions Holdings”), a wholly-owned subsidiary of the Company, as the guarantor, entered into a Credit Agreement with Bank of Montreal, as administrative agent (as subsequently amended, the “Credit Facility”). The Credit Facility consists of a $425.0 million term loan (the “Term Loan”), with an amortization equal to 1.00% per year, and a revolving loan facility (the “Revolving Loan”). On January 31, 2019, the Revolving Loan was amended to reduce the total availability from $25.0 million to $12.5 million, to extend the maturity date from July 31, 2019 to December 31, 2020, and to amend certain financial covenants. On December 23, 2019, the Revolving Loan was further amended to extend the maturity date from December 31, 2020 to April 1, 2021 and to amend one of the financial covenants.
The Revolving Loan includes a $10.0 million letter-of-credit sub-facility, issuances against which reduce the available capacity for borrowing. As of June 30, 2020, the Company had issued $0.03 million of letters of credit, against which no funds have been drawn. The Term Loan has a scheduled maturity date of July 31, 2021. The interest rates on borrowings under the facilities are either the alternate base rate plus 3.75% or LIBOR plus 4.75% per annum, with a 1.00% LIBOR floor (with step-downs in respect of borrowings under the Revolving Loan dependent upon the achievement of certain financial ratios). The obligations under the Credit Facility are secured by liens on substantially all of the assets of (a) AgroFresh Inc. and its direct wholly-owned domestic subsidiaries, and (b) AF Solutions Holdings LLC, including the common stock of AgroFresh Inc.
The net proceeds of the Term Loan were used to fund a portion of the purchase price payable to Dow in connection with the Business Combination. Amounts available under the Revolving Loan may also be used for working capital, general corporate purposes, and other uses, all as more fully set forth in the Credit Agreement. At June 30, 2020, there was $403.8 million outstanding under the Term Loan and no balance outstanding under the Revolving Loan.
As of the Closing Date, the Company incurred approximately $12.9 million in debt issuance costs related to the Term Loan and $1.3 million in costs related to the Revolving Loan. The debt issuance costs associated with the Term Loan were capitalized against the principal balance of the debt, and the Revolving Loan costs were capitalized in Other Assets. All issuance costs will be accreted through interest expense for the duration of each respective debt facility. The interest expense related to the amortization of the debt issuance costs during the three months ended June 30, 2020 and 2019, was approximately $0.6 million and $0.6 million, respectively. The interest expense related to the amortization of the debt issuance costs during the six months ended June 30, 2020 and 2019 was approximately $1.2 million and $1.1 million, respectively.
Certain restrictive covenants are contained in the Credit Facility, which includes the Revolving Loan, and the Company was in compliance with these covenants as of June 30, 2020, other than covenants that apply only to the Company's ability to borrow under the Revolving Loan (excluding letters of credit).
Beginning with the year ended December 31, 2016, the Company is required to prepay Term Loan Borrowings and Incremental Term Loan Borrowings in an aggregate amount equal to 50% of the "Excess Cash Flow" (as defined in the Credit Facility) for the fiscal year; provided that such amount of the Excess Cash Flow in any fiscal year shall be reduced by (i) the aggregate amount of prepayments of Term Loans and Incremental Term Loans made, (ii) to the extent accompanied by permanent reductions of Revolving Commitments, the aggregate amount of prepayments of Revolving Loans (other than prepayments financed with the proceeds of Indebtedness), and (iii) repaid borrowings of Revolving Loans made on the Effective Date to account for any additional original issue discount or upfront fees that are implemented pursuant to the Fee Letter provided further that, prepayments of Term Loan Borrowings and Incremental Term Loan Borrowings shall only be required if 50% of the Excess Cash Flow for such fiscal year exceeds $5.0 million. There are no amounts due under this provision as of June 30, 2020.
The Credit Facility was amended and restated on July 27, 2020. Refer to Note 22 – Subsequent Events for further information.
The Company entered into an interest rate swap contract in August 2019 to hedge interest rate risk associated with the Term Loan. During the three and six months ended June 30, 2020, an unrealized gain of $0.3 million and an unrealized loss of $0.7 million was recognized, respectively, in connection with this swap. The interest rate swap contract matures on December 31, 2020.
As part of the Coronavirus Aid, Relief, and Economic Security Act (the "CARES Act"), the Company received a Paycheck Protection Program ("PPP") loan to offset eligible costs incurred during the period. Under the terms of the PPP, PPP loans and accrued interest are forgivable after twenty-four weeks as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries during the forgiveness period.
16
As of June 30, 2020, the Company has used the entire loan proceeds to fund its eligible payroll expenses and mortgage interest. As a result, the Company believes that it has met the PPP eligibility criteria for forgiveness and has concluded that the loan represents, in substance, a government grant that is expected to be forgiven. As such, in accordance with IAS 20 “Accounting for Government Grants and Disclosure of Government Assistance”, the Company has recognized the entire loan amount as Grant Income at June 30, 2020.
The Company does not anticipate taking any action that would cause any portion of the loan to be ineligible for forgiveness. However, to the extent that any amount is deemed unforgivable, such amount is payable over to five years at an interest rate of 1%, with a deferral of payments for the first six months.
12. Leases
The Company enters into lease agreements for certain facilities and vehicles that are primarily used in the ordinary course of business. These leases are accounted for as operating leases, whereby lease expense is recognized on a straight-line basis over the term of the lease.
Most leases include an option to extend or renew the lease term. The exercise of the renewal option is at the Company's discretion. The operating lease liability includes lease payments related to options to extend or renew the lease term if the Company is reasonably certain of exercising those options. The Company, in determining the present value of lease payments, uses the Company’s incremental secured borrowing rate commensurate with the term of the underlying lease.
Lease expense is primarily included in general and administrative expenses in the condensed consolidated statements of operations. Additional information regarding the Company's operating leases is as follows:
(in thousands) | Three months ended June 30, 2020 | Three months ended June 30, 2019 | Six months ended June 30, 2020 | Six months ended June 30, 2019 | ||||||||||
Operating leases | $ | 648 | $ | 657 | $ | 1,254 | $ | 1,258 | ||||||
Short-term leases (1) | 89 | 16 | 176 | 47 | ||||||||||
Total lease expense | $ | 737 | $ | 673 | $ | 1,430 | $ | 1,305 |
(1) Leases with an initial term of twelve months or less are not recorded on the balance sheet.
Other information on operating leases | Six months ended June 30, 2020 | Six months ended June 30, 2019 | ||||||
Cash payments included in operating cash flows | $ | 854 | $ | 609 | ||||
Right-of-use assets obtained in exchange for new lease | $ | 795 | $ | 296 | ||||
Weighted average discount rate | 9.03 | % | 9.42 | % | ||||
Weighted average remaining lease term in years | 5.04 | 5.75 |
The following table presents the contractual maturities of the Company's lease liabilities as of June 30, 2020:
(in thousands) | Lease Liability | ||||
Remainder of 2020 | $ | 1,115 | |||
2021 | 2,011 | ||||
2022 | 1,699 | ||||
2023 | 1,423 | ||||
2024 and thereafter | 2,459 | ||||
Total undiscounted lease payments | 8,707 | ||||
Less: present value adjustment | 2,007 | ||||
Operating lease liability | $ | 6,700 |
The following table presents the contractual maturities of the Company's lease liabilities as of December 31, 2019:
17
(in thousands) | Future lease Payments | ||||
2020 | $ | 1,939 | |||
2021 | 1,670 | ||||
2022 | 1,509 | ||||
2023 | 1,294 | ||||
2024 and thereafter | 2,380 | ||||
Total undiscounted lease payments | 8,792 | ||||
Less: present value adjustment | 1,960 | ||||
Operating lease liability | $ | 6,832 |
13. Other Noncurrent Liabilities
The Company’s other noncurrent liabilities at June 30, 2020 and December 31, 2019 consisted of the following:
(in thousands) | June 30, 2020 | December 31, 2019 | ||||||
Lease liability | $ | 5,135 | $ | 5,339 | ||||
Other (1) | 1,430 | 1,907 | ||||||
Total other noncurrent liabilities | $ | 6,565 | $ | 7,246 |
(1) Other noncurrent liabilities include long-term rebates and pension liabilities.
14. Severance
Severance expense was $0.1 million and $0.2 million for the three months ended June 30, 2020 and 2019, respectively, and $0.1 million and $0.7 million for the six months ended June 30, 2020 and 2019, respectively. These amounts, which do not include stock compensation expense, were recorded in selling, general and administrative expense in the condensed consolidated statements of operations. As of June 30, 2020 and December 31, 2019, the Company had a $0.1 million and $0.4 million severance liability, respectively.
15. Stockholders’ Equity
The authorized common stock of the Company consists of 400,000,000 shares with a par value of $0.0001 per share. Holders of the Company’s common stock are entitled to one vote for each share of common stock. As of June 30, 2020, there were 52,213,708 shares of common stock outstanding. As of June 30, 2020, there were warrants to purchase 15,983,072 shares of the Company’s common stock outstanding at a strike price of $11.50. Of the 15,983,072 warrants, 9,823,072 were issued as part of the units sold in the Company's initial public offering in February 2014 (1,201,928 warrants were subsequently repurchased during 2015) and 6,160,000 warrants were sold in a private placement at the time of such public offering.
On June 13, 2020, the Company entered into an Investment Agreement (the “Investment Agreement”) with the Investor, an affiliate of Paine Schwartz Partners, LLC (“PSP”), pursuant to which, subject to certain closing conditions, the Investor agreed to purchase in a private placement an aggregate of $150,000,000 of convertible preferred equity of the Company. The transaction closed on July 27, 2020 and a total of 150,000 shares of the Company’s newly-designated Series B-1 Convertible Preferred Stock, par value $0.0001 per share (the “Series B-1 Preferred Stock”) were purchased in such transaction (the “Private Placement”). Following the approval of the transactions contemplated by the Investment Agreement by the necessary regulatory body, the Company will be required to issue to the Investor, for no additional consideration, a total of 150,000 shares of the Company’s newly-designated Series B-2 Convertible Preferred Stock, par value $0.0001 per share (the “Series B-2 Preferred Stock”). Shortly thereafter, all of the outstanding shares of Series B-1 Preferred Stock and Series B-2 Preferred Stock would be exchanged for a total of 150,000 shares of the Company’s newly-designated Series B Convertible Preferred Stock, par value $0.0001 per share (the “Series B Preferred Stock” and, together with the Series B-1 Preferred Stock, the “Preferred Stock”).
The Series B-1 Preferred Stock ranks (and, when issued, the Series B Preferred Stock will rank) senior to the shares of the Company’s common stock, with respect to dividend rights and rights on the distribution of assets on any voluntary or involuntary liquidation, dissolution or winding up of the affairs of the Company. The Series B-1 Preferred Stock has (and, when issued, the Series B Preferred Stock will have) a liquidation preference of $1,000 per share (the “Stated Value”). Holders of the Series B-1 Preferred Stock are (and, when issued, the Series B Preferred Stock will be) entitled to a cumulative dividend at a rate of 16% per
18
annum, of which 50% will be payable in cash and 50% will be payable in kind until the first anniversary of the Closing Date, after which 50% will be payable in cash, 37.5% will be payable in kind, and the remaining 12.5% will be payable in cash or in kind, at the Company’s option, subject in each case to adjustment under certain circumstances. Dividends on the Series B-1 Preferred Stock are (and, when issued, the Series B Preferred Stock will be) cumulative and payable quarterly in arrears. All dividends that are paid in kind will accrete to, and increase, the Stated Value. The applicable dividend rate is subject to increase by 2% per annum during any period that the Company is in breach of certain provisions of the applicable Certificate of Designation of the Preferred Stock.
The Preferred Stock will be convertible into Common Stock at the election of the holder at any time at an initial conversion price of $5.00 (the “Conversion Price”), subject to certain limitations. The Conversion Price is subject to customary adjustments, including for stock splits and other reorganizations affecting the Common Stock and pursuant to certain anti-dilution provisions for below market issuances. Refer to Note 22 – Subsequent Events for additional information.
In December 2018, the Company filed a shelf registration statement (File No. 333-229002) (“Form S-3 Shelf”) with the Securities and Exchange Commission, that became effective in February 2019. On June 25, 2020, the Company established an at-the-market offering facility (the “ATM Facility”) under the Form S-3 Shelf, with Virtu Americas LLC, acting as sales agent with support from H.C. Wainwright & Co and Roth Capital Partners. The Company’s board of directors approved sales of up to $30,000,000 maximum aggregate offering of the Company’s common stock under the ATM Facility. There were no shares of the Company’s common stock issued under the ATM Facility through June 30, 2020.
In connection with and as a condition to the consummation of the Business Combination, the Company issued R&H one share of Series A Preferred Stock. R&H, voting as a separate class, is entitled to appoint one director to the Company’s board of directors for so long as R&H beneficially holds 10% or more of the aggregate amount of the outstanding shares of common stock and non-voting common stock of the Company. The Series A Preferred Stock has no other rights.
16. Stock-based Compensation
In July 2015, the Company adopted the 2015 Incentive Compensation Plan (as amended, the “Plan”), pursuant to which the Compensation Committee of the Company is authorized to grant up to 7,150,000 shares to officers and employees of the Company, in the form of equity-based awards, including time or performance based options and restricted stock.
In June 2019, the Company's shareholders approved the 2019 Employee Stock Purchase Plan (the "ESPP"), which was effective July 1, 2019. 500,000 shares of common stock are reserved for issuance under the ESPP. As of June 30, 2020, 253,042 shares had been issued under the ESPP.
Stock compensation expense for equity-classified and liability-classified awards was $1.0 million and $0.6 million for the three months ended June 30, 2020 and 2019, respectively. Stock compensation expense for equity-classified and liability-classified awards was $1.8 million and $1.2 million for the six months ended June 30, 2020 and 2019, respectively. Stock compensation expense is recognized in cost of goods sold, selling, general and administrative expenses and research and development expenses. At June 30, 2020, there was $5.7 million of unrecognized compensation cost relating to outstanding unvested equity instruments expected to be recognized over the weighted average period of 2.1 years.
On April 14, 2020, the Company granted the following share-based awards to members of management employed in the United States. These awards will be settled in shares of the Company's common stock and are equity-classified. The grant date fair value of the time-based award will be recognized on a straight-line basis over the vesting period. The grant date fair value of the performance-based award will be recognized on a straight-line basis over the vesting period based on the probability of achieving the performance condition. The performance-based restricted stock units each have a performance period that ends on December 31, 2022.
Number of shares | |||||
Time-based restricted stock | 1,004,979 | ||||
Performance-based restricted stock units | 896,766 | ||||
Total | 1,901,745 |
On April 14, 2020, the Company also granted the following share-based awards to members of management employed in countries outside of the United States. These awards will be settled in cash and are liability-classified. Therefore, the fair value of these liability-classified awards will be re-measured on each balance sheet date. The performance-based phantom shares each have a performance period that ends on December 31, 2022.
19
Number of shares | |||||
Time-based phantom shares | 163,462 | ||||
Performance-based phantom shares | 83,704 | ||||
Total | 247,166 |
The performance-based restricted stock units and phantom shares were valued with a Monte Carlo simulation model using the assumptions in the table below. Based on these assumptions, the grant date fair value of the performance-based restricted stock units was estimated to be $1.70 per share.
Volatility | 65.8 | % | |||
Risk-free interest rate | 0.27 | % | |||
Dividend yield | — | % | |||
Grant date stock price | $1.65 | ||||
Performance period | 3.0 years |
The fair value of the time-based restricted stock and the time-based phantom shares is equal to the closing price of the Company’s common stock on the grant date of the awards.
17. Earnings Per Share
Basic earnings (loss) per share is calculated by dividing net income (loss) by the weighted average number of common shares outstanding for the period. The Company had a loss for the three and six months ended June 30, 2020 and 2019. Therefore, the effect of stock-based awards including options, restricted stock, restricted stock units and warrants outstanding at June 30, 2020 and 2019, respectively, have not been included in the computation of diluted loss per share because their inclusion would have been anti-dilutive.
The following is a reconciliation of the weighted-average common shares outstanding used for the computation of basic and diluted net (loss) income per common share:
Three Months Ended June 30, 2020 | Three Months Ended June 30, 2019 | Six Months Ended June 30, 2020 | Six Months Ended June 30, 2019 | |||||||||||
Basic weighted-average common shares outstanding | 50,758,273 | 50,146,513 | 50,646,522 | 50,094,822 | ||||||||||
Effect of dilutive options, performance stock units and restricted stock | — | — | — | — | ||||||||||
Diluted weighted-average shares outstanding | 50,758,273 | 50,146,513 | 50,646,522 | 50,094,822 |
20
Securities that could potentially be dilutive are excluded from the computation of diluted (loss) income per share when a loss from continuing operations exists, when the exercise price exceeds the average closing price of the Company's common stock during the period, or for contingently issued shares, if the contingency is not met at the end of the reporting period, because their inclusion would result in an anti-dilutive effect on per share amounts.
The following represents the weighted-average number of shares that could potentially dilute basic earnings per share in the future:
Three Months Ended June 30, 2020 | Three Months Ended June 30, 2019 | Six Months Ended June 30, 2020 | Six Months Ended June 30, 2019 | |||||||||||
Stock-based compensation awards(1): | ||||||||||||||
Stock options | 860,588 | — | 861,766 | — | ||||||||||
Restricted stock to non-directors | 1,268,010 | 188,168 | 930,421 | 212,271 | ||||||||||
Restricted stock to directors | — | 148,284 | — | 140,106 | ||||||||||
Warrants: | ||||||||||||||
Private placement warrants | 6,160,000 | 6,160,000 | 6,160,000 | 6,160,000 | ||||||||||
Public warrants | 9,823,072 | 9,823,072 | 9,823,072 | 9,823,072 |
(1) SARs and Phantom Shares are payable in cash so will have no impact on number of shares.
Warrants and options are considered anti-dilutive and excluded when the exercise price exceeds the average market value of the Company’s common stock price during the applicable period.
18. Income Taxes
The provision for income taxes consists of provisions for federal, state and foreign incomes taxes. The effective tax rates for the periods ended June 30, 2020 and June 30, 2019, reflect the Company’s expected tax rate on reported income (loss) from continuing operations before income tax and tax adjustments. The Company operates in a global environment with significant operations in the U.S. and various other jurisdictions outside the U.S. Accordingly, the consolidated income tax rate is a composite rate reflecting the Company’s earnings and the applicable tax rates in the various jurisdictions where the Company operates.
On March 27, 2020, President Trump signed into law the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act. The CARES Act includes tax changes and financial aid designed to protect the American people from the public health and economic impacts of COVID-19. The tax changes include allowing net operating losses to be carried back five years, suspending the 80% of taxable limitation on the use of net operating losses, an increase of the 30% of EBITDA limitation on the deduction of interest expense to 50%, and acceleration of the refund for alternative minimum tax credits granted under the 2017 Tax Cuts and Jobs Act (“TCJA”). Most significant to the Company are the modifications on the limitation of business interest deductions for tax years beginning in 2019 and 2020. The modifications to Section 163(j) increase the allowable business interest deduction from 30% to 50% of adjusted taxable income.
Typically, the Company has calculated its provision for income taxes during its interim reporting periods by applying an estimate of the annual effective tax rate for the full year "ordinary" income or loss for the respective reporting period. For the six months ended June 30, 2020, the Company has computed its provision for income taxes under the discrete method which allows the Company to calculate its tax provision based upon the actual effective tax rate for the year-to-date. The discrete method was determined to be an appropriate method for estimating its tax provision for the six months ended June 30, 2020 as it provides a reliable estimate as opposed to changes in estimated "ordinary" income or loss which would have resulted in significant fluctuations when estimating the annual effective tax rate.
The Company's effective tax rate for the three and six months ended June 30, 2020 was (3.9)% and 13.5%, respectively, compared to the effective tax rate for the three and six months ended June 30, 2019 of 22.0% and 16.4%, respectively.
The effective tax rate for the six months ended June 30, 2020 differs from the U.S. statutory tax rate of 21%, primarily because of changes in valuation allowance positions related to the United States and certain foreign jurisdictions and by foreign exchange currency gains, offset by foreign provision to return tax benefits, primarily in France.
21
The sale of the Series B-1 Preferred Stock (see Note 22 – Subsequent Events) triggered a change in control as defined in Sections 382 and 383 of the Internal Revenue Code. Those provisions limit the utilization of certain US tax carryforwards and net built in losses. The Company is in the process of determining the limitation and related impact on the use of its tax attributes.
19. Segment Information
The authoritative guidance for disclosures about segments of an enterprise establishes standards for reporting information about segments. It defines operating segments as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision-maker in deciding how to allocate resources and in assessing performance. We currently operate and manage our business as two operating segments. Our chief operating decision-makers allocate resources and assess performance of the business for each segment. Accordingly, we consider ourselves to have two operating and reportable segments (i) AgroFresh core and (ii) Tecnidex. AgroFresh core business is providing produce preservation and waste prevention solutions for growers and packers. Its products include SmartFresh, Harvista, RipeLock and FreshCloud. Tecnidex is a provider of fungicides, disinfectants, waxes and coatings primarily focused on the citrus market.
Our chief operating decision-makers do not evaluate operating segments using asset or liability information. The following table presents a breakdown of our revenues and gross profit based on reportable segments for the three and six months ended June 30, 2020 and 2019.
(in thousands) | Three Months Ended June 30, 2020 | Three Months Ended June 30, 2019 | Six Months Ended June 30, 2020 | Six Months Ended June 30, 2019 | ||||||||||
AgroFresh Core | ||||||||||||||
Revenues | $ | 16,738 | $ | 16,867 | $ | 45,380 | $ | 50,355 | ||||||
Gross Profit | 12,402 | 13,364 | 34,797 | 38,497 | ||||||||||
Tecnidex | ||||||||||||||
Revenues | 3,244 | 4,316 | 7,625 | 9,768 | ||||||||||
Gross Profit | 1,127 | 1,530 | 3,227 | 4,002 | ||||||||||
Total Revenues | $ | 19,982 | $ | 21,183 | $ | 53,005 | $ | 60,123 | ||||||
Total Gross Profit | $ | 13,529 | $ | 14,894 | $ | 38,024 | $ | 42,499 |
20. Commitments and Contingencies
The Company is currently involved in various claims and legal actions that arise in the ordinary course of business. The Company has recorded reserves for loss contingencies based on the specific circumstances of each case. Such reserves are recorded when it is probable that a loss has been incurred as of the balance sheet date and can be reasonably estimated. Although the results of litigation and claims can never be predicted with certainty, the Company does not believe that the ultimate resolution of these actions will have a material adverse effect on the Company’s business, financial condition or results of operations.
On October 14, 2019, the Company was awarded a verdict of $31.1 million in damages, related to, among other things, trade secret misappropriation and willful patent infringement, in its litigation against Decco Post-Harvest, Inc. ("Decco") and Decco's parent company, UPL Limited. The award is subject to post-verdict review by the Court and any appeals that may be taken by the parties in the future.
In July 2020, three separate putative class action lawsuits were filed against the Company, each alleging that the Company’s disclosures regarding the transactions contemplated by the Investment Agreement contained in its proxy statement for the 2020 annual meeting of the Company’s stockholders were inadequate.
Purchase Commitments
The Company has various purchasing contracts for contract manufacturing and research and development services which are based on the requirements of the business. Generally, the contracts are at prices not in excess of current market prices and do not commit the business to obligations outside the normal customary terms for similar contracts.
22
21. Fair Value Measurements
Liabilities Measured at Fair Value on a Recurring Basis
The following table presents the fair value of the Company’s financial instruments that are measured at fair value on a recurring basis as of June 30, 2020:
(in thousands) | Level 1 | Level 2 | Level 3 | Total | ||||||||||
Liability-classified stock compensation (1) | $ | — | $ | — | $ | 265 | $ | 265 | ||||||
Interest rate swap | — | — | 579 | 579 | ||||||||||
Total | $ | — | $ | — | $ | 844 | $ | 844 |
The following table presents the fair value of the Company’s financial instruments that are measured at fair value on a recurring basis as of December 31, 2019:
(in thousands) | Level 1 | Level 2 | Level 3 | Total | ||||||||||
Liability-classified stock compensation (1) | $ | — | $ | — | $ | 218 | $ | 218 | ||||||
Interest rate swap | — | — | (95) | (95) | ||||||||||
Total | $ | — | $ | — | $ | 123 | $ | 123 |
(1) The fair values of phantom stock units were estimated using a Monte Carlo simulation pricing model with the assumptions described below:
June 30, 2020 | |||||||||||
Grant date fair value | $ | 1.70 | — | $7.28 | |||||||
Risk-free interest rate | 0.27 | % | — | 2.39% | |||||||
Expected life (years) | 2.71 | — | 2.75 | ||||||||
Estimated volatility factor | 65.1 | % | — | 69.9% | |||||||
Expected dividends | None |
There were no transfers between Level 1 and Level 2 and no transfers out of Level 3 of the fair value hierarchy during the six months ended June 30, 2020.
At June 30, 2020, the Company evaluated the amount recorded under the Term Loan and determined that the fair value was approximately $391.6 million. The carrying amounts of cash and cash equivalents, accounts receivable, and accounts payable approximate fair value.
Changes in Financial Instruments Measured at Level 3 Fair Value on a Recurring Basis
The following table presents the changes during the period presented in the Company's Level 3 financial instrument liabilities that are measured at fair value on a recurring basis.
(in thousands) | Liability-classified stock compensation | Interest rate swap | Total | ||||||||
Balance, December 31, 2019 | $ | 218 | $ | (95) | $ | 123 | |||||
Stock compensation activity | 47 | — | 47 | ||||||||
Mark-to-market adjustment | — | 674 | 674 | ||||||||
Balance, June 30, 2020 | $ | 265 | $ | 579 | $ | 844 |
22. Subsequent events
On July 27, 2020, the Company completed a comprehensive refinancing by entering into an Amended and Restated Credit Agreement (the “Restated Credit Agreement”) with the other loan parties party thereto, Bank of Montreal, as administrative agent (“Administrative Agent”) and the lenders party thereto. The Restated Credit Agreement amends and restates in its entirety the Credit Agreement.
23
The Restated Credit Agreement provides for a $25 million revolving credit facility (the “Revolving Credit Facility”) which matures on June 30, 2024, and a $275 million term credit facility (the “Term Credit Facility” and, together with the Revolving Credit Facility, the “Restated Credit Facility”), which matures on December 31, 2024. The Restated Credit Facility includes a $5 million swingline commitment and a $10 million letter of credit sub-limit.
Loans under the Term Credit Facility bear interest at a rate equal to, at the Company’s option, either the Adjusted Eurodollar Rate for the interest period in effect for such borrowing plus an Applicable Rate of 6.25% per annum, or the Alternate Base Rate plus an Applicable Rate of 5.25% per annum. Loans under the Revolving Credit Facility bear interest at a rate equal to, at the Company’s option, the Adjusted Eurodollar Rate for the interest period in effect for such borrowing plus the Applicable Rate ranging from 6.25% to 6.00% per annum, based on certain ratios. The Company is also required to pay a commitment fee on the unused portion of the Revolving Credit Facility at a rate ranging from 0.5% to 0.375%, based on certain ratios. The Company is required to make mandatory prepayments of outstanding indebtedness under the Restated Credit Agreement under certain circumstances.
On the closing date of the Company’s Credit Agreement, the Company consummated the issuance and sale of 150,000 shares of the Company’s newly-designated Series B-1 Convertible Preferred Stock, pursuant to the terms of the Investment Agreement. See Note 15 – Stockholders’ Equity for additional information.
In connection with the consummation of the Investment Agreement, the Company and the Investor entered into a Registration Rights Agreement (the “Registration Rights Agreement”), dated as of July 27, 2020. The Registration Rights Agreement provides that the Company will use its commercially reasonable efforts to prepare and file a shelf registration statement with the SEC and to use its commercially reasonable efforts to cause such shelf registration statement to be declared effective as promptly as is reasonably practicable after its filing to permit the public resale of registrable securities covered by the Registration Rights Agreement.
In July 2020, AgroFresh Spain, S.L.U. entered into a €0.6 million loan agreement with Banco Santander, S.A., which provides funding through July 2025 at a 2.5% interest rate.
24
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
As used in this Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”), the terms “Company,” “AgroFresh,” “we,” “us” and “our” refer to AgroFresh Solutions, Inc. and its consolidated subsidiaries, unless the context otherwise requires or it is otherwise indicated.
The following discussion and analysis of the Company’s financial condition and results of operations should be read in conjunction with the unaudited condensed consolidated financial statements and the notes thereto contained elsewhere in this Report.
This MD&A contains the financial measures EBITDA and Adjusted EBITDA, which are not presented in accordance with accounting principles generally accepted in the United States of America ("GAAP"). These non-GAAP financial measures are being presented because management believes that they provide readers with additional insight into the Company’s operational performance relative to earlier periods and relative to its competitors and they are key measures used by the Company to evaluate its performance. The Company does not intend for these non-GAAP financial measures to be a substitute for any GAAP financial information. Readers of this MD&A should use these non-GAAP financial measures only in conjunction with the comparable GAAP financial measures. A reconciliation of EBITDA and Adjusted EBITDA to the most comparable GAAP measure is provided in this MD&A.
Note Regarding Forward-Looking Statements
All statements other than statements of historical fact included in this Report including, without limitation, statements in this MD&A regarding the Company's financial position, business strategy and the plans and objectives of management for future operations, are forward looking statements. When used in this Report, words such as “anticipate,” “believe,” “estimate,” “expect,” “intend” and similar expressions, as they relate to the Company or its management, identify forward looking statements. Such forward looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. Actual results and/or the timing of events could differ materially from those contemplated by these forward-looking statements due to a number of factors, including those discussed under the heading “Risk Factors” in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2019 (the "2019 Form 10-K") as well as the update to those Risk Factors disclosed in Part II, Item 1A of this Report. Any forward-looking statements included in this Report are based only on information currently available to the Company and speak only as of the date on which such statements are made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. All subsequent written or oral forward-looking statements attributable to the Company or persons acting on behalf of the Company are qualified in their entirety by this paragraph.
Business Overview
AgroFresh is a global leader in delivering innovative food quality preservation and waste prevention solutions for fresh produce. The Company is empowering the food industry with a range of integrated solutions designed to help growers, packers and retailers improve produce freshness and quality while reducing waste. AgroFresh has key products registered in over 50 countries and supports customers with over 25,000 storage rooms globally. AgroFresh has an extensive portfolio of freshness solutions ranging from LandSpringTM for transplanted seedlings, near-harvest with HarvistaTM and post-harvest including its flagship SmartFreshTM technology. Additional post-harvest freshness solutions include fungicides that can be applied to meet various customer operational requirements, in either a foggable (ActiMist™) or liquid (ActiSeal™) delivery form. To supplement our near- and post-harvest product solutions, our suite of FreshCloud™ analytical, diagnostic and tracking services provide a range of value-added capabilities that help customers optimize the quality of their produce. Beyond apples, SmartFresh technology can provide ready-to-eat freshness for other fruits and vegetables including avocados, bananas, melons, tomatoes, broccoli and mangos. AgroFresh is also providing customers with packaging-based advisory services and custom packaging solutions including RipeLock, our packaging-based freshness technology solutions for fruits and vegetables.
In December 2017, AgroFresh acquired a controlling interest in Tecnidex. With this acquisition, AgroFresh expanded its post-harvest presence into additional crops, and increased its penetration of the produce market in southern Europe, Latin America and Africa. This acquisition expanded AgroFresh's product portfolio into waxes and coatings and reinforced its position in fungicides. For over 35 years, Tecnidex has been helping fruit and vegetable producers offer clean, safe and high-quality produce to customers, now reaching 18 countries. Through its portfolio of post-harvest fungicides, coatings, waxes, disinfectants, equipment and associated consulting and after-sale services, Tecnidex improves the quality and value of its clients’ fruit and vegetables while respecting the environment. Tecnidex further diversified AgroFresh’s revenue by expanding the Company's ability to provide solutions and service to the citrus industry.
25
Freshness is the most important driver of consumer satisfaction when it comes to produce and, at the same time, lack of freshness results in waste which is a major issue in the industry. About one third of the total food produced worldwide is lost or wasted each year. Nearly 45% of all fresh fruits and vegetables, 40% of apples and 20% of bananas, are lost to spoilage. AgroFresh plays a key role in the value chain by offering products and services that maintain produce freshness and reduce waste.
AgroFresh’s current flagship product, SmartFresh, regulates the post-harvest ripening effects of ethylene, the naturally occurring plant hormone that triggers ripening in certain fruits and vegetables. SmartFresh is naturally biodegradable, leaves no detectable residue and has been approved for use by many domestic and global regulatory organizations. Harvista extends the Company’s proprietary technology into the field, including treatment of cherries and blueberries early in the growing season and near-harvest management of apples and pears. FreshCloud Storage InsightsTM is an atmospheric monitoring system that leverages the Company's extensive understanding of fruit physiology, fruit respiration, controlled atmosphere technology and new proprietary diagnostic tools to provide improved real-time guidance to producers and packers of fresh produce regarding storage conditions so timely corrective measures can be taken. LandSpringTM is an innovative 1-MCP technology targeted to transplanted vegetable seedlings. It is currently registered for use on tomatoes, peppers and 14 other crops in the US. It reduces transplant shock, resulting in less seedling mortality and faster crop establishment, which leads to a healthier crop and improved yields.
AgroFresh’s business is highly seasonal, driven by the timing of harvests in the northern and southern hemispheres. For apples and pears, the first half of the year is when the southern hemisphere harvest occurs and the second half of the year is when the northern hemisphere harvest occurs. Since the northern hemisphere harvest of apples, our primary crop, is typically larger, a significant portion of our sales and profits are historically generated in the second half of the year. In addition to this seasonality, factors such as weather patterns may impact the timing of the harvest within the two halves of the year. Diversifying into other crops is a key strategy to balance seasonality, therefore there is a strategic importance of the Tecnidex acquisition since the citrus harvest in northern hemisphere countries occurs in the last and first quarters of the year.
On July 31, 2015 (the “Closing Date”), we consummated a business combination (the “Business Combination”) pursuant to a Stock Purchase Agreement, dated April 30, 2015 (the “Purchase Agreement”), with Dow, providing for the acquisition by us of the AgroFresh business from Dow. In connection with the closing of the Business Combination, we entered into a tax receivables agreement (the "TRA"), as amended in April 2017, pursuant to which Dow was entitled to receive 50% of the tax savings, if any, that the Company realized as a result of the increase in the tax basis of assets acquired pursuant to the Business Combination. The TRA was terminated in December 2019. Also in connection with the closing of the Business Combination, AgroFresh entered into a transition services agreement with Dow. Under the agreement, Dow provided AgroFresh a suite of services for a period of time ranging from six months to five years depending on the service. While most of the Dow-provided services were complete as of December 31, 2018, certain services are expected to continue through 2020.
Factors Affecting the Company’s Results of Operations
The Company’s results of operations are affected by a number of external factors. Some of the more important factors are briefly discussed below.
Impact of COVID-19
In March 2020, the COVID-19 outbreak was declared a National Public Health Emergency which continues to spread throughout the world and has adversely impacted global activity and contributed to significant declines and volatility in financial markets. The outbreak could have a continued material adverse impact on economic and market conditions and trigger a period of global economic slowdown. For the three months ended June 30, 2020, the Company did not experience significant disruptions to operations or supply chains and results have not been materially impacted. However, there were numerous obstacles presented and some localized financial impacts of the pandemic, including the weakening of foreign currencies. While we are following the requirements of governmental authorities and taking additional preventative and protective measures to ensure the safety of our workforce, including implementing remote working arrangements and varying procedures for essential workforce, we cannot be certain that there will not be any incidents across our global operations that may cause service interruptions. The rapid development and fluidity of this situation precludes any prediction as to the ultimate material adverse impact of the coronavirus outbreak, although the Company operates in an industry that thus far has not been as severely impacted as others. Nevertheless, the outbreak presents some uncertainty and risk with respect to the Company and its performance and financial results.
Demand for the Company’s Offerings
The Company services customers in over 50 countries and derives its revenue by assisting growers and packers to optimize the value of their crops primarily through the post-harvest period. Its products and services add value to customers by reducing
26
food spoilage and extending the life of perishable fruits. The U.S. Food and Agriculture Organization of the United Nations has estimated that a growing global population will require a near doubling of food production in developing countries by 2050 to meet the expected demand of a worldwide population of 9 billion people.
This global trend, among others, creates demand for the Company’s solutions. The Company’s offerings are currently protected by patent filings in 51 countries.
The global produce market is a function of both the size and the yield of the crop harvested, and variations in either will affect total production. Given the nature of the agricultural industry, weather patterns may impact total production and the Company's resulting commercial opportunities. The Company supports a diverse customer base whose end markets vary due to the type of fruit and quality of the product demanded in their respective markets. Such variation across end markets also affects demand for the Company’s services.
Customer Pricing
The Company’s service offerings are priced based on the value they provide to the Company’s customers. From time to time, the Company may adjust its pricing policy to incorporate new offerings or address market and volume trends. The Company does not typically price its products in relation to any underlying cost of materials or services; therefore, its margins can fluctuate with changes in these costs. The Company’s pricing may include rebate arrangements with customers in exchange for mutually beneficial long-term relationships and growth.
Integrated Service Model
AgroFresh uses a direct service model to offer the Company’s commercially available products, including SmartFresh and Harvista. Sales and technical support personnel maintain face-to-face relationships with customers year round. Technical sales and support personnel work directly with customers to provide value-added advisory services regarding the application of SmartFresh. The actual application of SmartFresh is performed by service providers that are typically third-party contractors or, for some product variations, made by our customers directly. The Harvista application service, through both aerial and ground application, is also administered by third-party service providers or made by our customers directly.
Most of the Company’s service providers are operating under multi-year contracts. Management believes the quality and experience of its service providers deliver clear commercial benefits.
Seasonality
The Company’s operations are subject to seasonal variation due to the timing of the growing seasons around the world. For our core crops of apples and pears, northern hemisphere growers harvest from August through November, and southern hemisphere growers harvest from late January to early May. As we diversify into other crops, such as citrus, we also anticipate seasonal variations in this business due to the northern hemisphere citrus harvest, which spans from October to March. Since the majority of the Company’s sales are in northern hemisphere countries, a proportionately greater share of its revenue is realized during the second half of the year. There are also variations in the seasonal demands from year to year depending on weather patterns and crop size. This seasonality and variations in seasonal demand could impact the ability to compare results between periods.
Foreign Currency Exchange Rates
With a global customer base and geographic footprint, the Company generates revenue and incurs costs in a number of different currencies, with the Euro comprising the most significant non-U.S. currency. Fluctuations in the value of these currencies relative to the U.S. dollar can increase or decrease the Company’s overall revenue and profitability as stated in U.S. dollars, which is the Company’s reporting currency. In certain instances, if sales in a given geography have been adversely impacted on a long-term basis due to foreign currency depreciation, the Company has been able to adjust its pricing so as to mitigate the impact on profitability.
Domestic and Foreign Operations
The Company has both domestic and foreign operations. Fluctuations in foreign exchange rates, regional growth-related spending in research and development (“R&D”) and marketing expenses, and changes in local selling prices, among other factors, may impact the profitability of foreign operations in the future.
27
Critical Accounting Policies and Use of Estimates
Critical accounting policies are those accounting policies that can have a significant impact on the presentation of our financial condition and results of operations and that require the use of complex and subjective estimates based upon management’s judgment. Because of the uncertainty inherent in such estimates, actual results may differ materially from these estimates. There have been no material changes to our critical accounting policies and estimates previously disclosed in the 2019 Form 10-K. For a description of our critical accounting policies and estimates as well as a listing of our significant accounting policies, see “Management's Discussion and Analysis of Financial Condition and Results of Operations - Critical Accounting Policies and Use of Estimates” and “Note 2 - Basis of Presentation and Summary of Significant Accounting Policies” in the 2019 Form 10-K.
28
Results of Operations
The following table summarizes the results of operations for the three and six months ended June 30, 2020 and June 30, 2019:
(in thousands) | Three Months Ended June 30, 2020 | Three Months Ended June 30, 2019 | Six Months Ended June 30, 2020 | Six Months Ended June 30, 2019 | ||||||||||
Net sales | $ | 19,982 | $ | 21,183 | $ | 53,005 | $ | 60,123 | ||||||
Cost of sales (excluding amortization, shown separately below) | 6,453 | 6,289 | 14,981 | 17,624 | ||||||||||
Gross profit | 13,529 | 14,894 | 38,024 | 42,499 | ||||||||||
Research and development expenses | 2,895 | 3,257 | 5,537 | 7,154 | ||||||||||
Selling, general and administrative expenses | 12,722 | 16,148 | 26,431 | 32,046 | ||||||||||
Amortization of intangibles | 10,936 | 11,766 | 21,893 | 23,382 | ||||||||||
Impairment of long lived assets | — | 992 | — | 992 | ||||||||||
Change in fair value of contingent consideration | — | 167 | — | 357 | ||||||||||
Grant income | (2,974) | — | (2,974) | — | ||||||||||
Operating loss | (10,050) | (17,436) | (12,863) | (21,432) | ||||||||||
Other (expense) income | (7) | (26) | 1,500 | (38) | ||||||||||
Gain (loss) on foreign currency exchange | 449 | (2,519) | 1,076 | (2,938) | ||||||||||
Interest expense, net | (6,513) | (8,670) | (13,479) | (17,415) | ||||||||||
Loss before income taxes | (16,121) | (28,651) | (23,766) | (41,823) | ||||||||||
Income taxes expense (benefit) | 630 | (6,290) | (3,201) | (6,877) | ||||||||||
Net loss including non-controlling interests | (16,751) | (22,361) | (20,565) | (34,946) | ||||||||||
Less: Net loss attributable to non-controlling interests | (197) | (92) | (363) | (58) | ||||||||||
Net loss attributable to AgroFresh Solutions, Inc | $ | (16,554) | $ | (22,269) | $ | (20,202) | $ | (34,888) |
Comparison of Results of Operations for the three months ended June 30, 2020 compared to the three months ended June 30, 2019.
Net Sales
Net sales were $20.0 million for the three months ended June 30, 2020, as compared to net sales of $21.2 million for the three months ended June 30, 2019, a decrease of 5.7%. The impact of the change in foreign currency exchange rates compared to the second quarter of 2019 reduced revenue by $1.7 million. Excluding this impact, revenue increased approximately 2.4%. The net sales increase on a constant currency basis was primarily the result of growth of SmartFresh in the Asia-Pacific region, as well as a positive contribution from our SmartFresh diversification strategy.
Cost of Sales
Cost of sales was $6.5 million for the three months ended June 30, 2020 as compared to $6.3 million for the three months ended June 30, 2019. Gross profit margin was 67.7% for the three months ended June 30, 2020 versus 70.3% for the three months ended June 30, 2019. The lower gross margin was primarily the result of negative fixed cost leverage on lower reported sales volumes, inventory valuation and revenue mix.
Research and Development Expenses
Research and development expenses were $2.9 million and $3.3 million, respectively, for the three months ended June 30, 2020 and June 30, 2019. The decrease in research and development expenses was partially driven by timing of projects.
Selling, General and Administrative Expenses
Selling, general and administrative expenses were $12.7 million for the three months ended June 30, 2020 compared to $16.1 million for the three months ended June 30, 2019, a decrease of 21.2%. Included in selling, general and administrative expenses were $0.7 million in the current year and $2.0 million in the prior year of costs associated with non-recurring items that included M&A, litigation, refinancing and severance costs. Excluding these items, selling general and administrative expenses decreased
29
approximately 15.0% in the second quarter versus the prior year period, which reflects the Company's ongoing cost optimization initiatives, as well as a temporary decrease in travel and other miscellaneous expenses as a result of the global pandemic.
Amortization of Intangibles
Amortization of intangible assets was $10.9 million for the three months ended June 30, 2020 compared to $11.8 million for the three months ended June 30, 2019. The reduction in the amortization expense for the three months ended June 30, 2020 is due to the accelerated amortization of RipeLock in December 2019 of $38.0 million, which resulted in lower quarterly amortization of $0.6 million.
Impairment of Intangibles
There were no indicators of impairment during the three months ended June 30, 2020. The Company recorded an impairment charge of $1.0 million during the three months ended June 30, 2019 associated with the Verigo software following a partnership agreement with a new technology provider.
Change in Fair Value of Contingent Consideration
The Company recorded no gain or loss for the three months ended June 30, 2020 related to a change in the fair value of contingent consideration, as compared to a $0.2 million loss in the three months ended June 30, 2019. As discussed in Note 3 - Business Combinations and Asset Acquisition of the unaudited condensed consolidated financial statements, pursuant to the Business Combination the Company entered into various forms of contingent consideration, including the tax amortization benefit contingency. These liabilities are measured at fair value each reporting date and any mark-to-market fluctuations are recognized in earnings. In December 2019, the TRA with Dow was terminated, and the Company paid to Dow an aggregate of $16 million in settlement of all past and estimated future liabilities that would have been owed under the TRA. The fair value adjustment of the contingent consideration related to the Tecnidex acquisition was settled in 2019.
Grant Income
The Company recorded income of $3.0 million in the three months ended June 30, 2020. Pursuant to the CARES Act, the Company received a Paycheck Protection Program loan to offset eligible costs incurred during the period. As the Company believes it is in compliance with the forgiveness criteria applicable to this loan program, the full amount was recognized as grant income.
Interest Expense, Net
Interest expense was $6.5 million for the three months ended June 30, 2020, as compared to $8.7 million for the three months ended June 30, 2019. The decrease was primarily due to $1.8 million lower interest on the Term Loan (as defined below) due to a lower variable rate and $0.8 million lower accretion on the TRA due to the settlement of the TRA in December 2019.
Gain (Loss) on Foreign Currency
Gain on foreign currency was $0.4 million for the three months ended June 30, 2020, as compared to a loss of $2.5 million for the three months ended June 30, 2019.
During the three months ended June 30, 2020, foreign currency gains were recognized related to U.S. dollar intercompany payables to the Brazilian real, which grew weaker relative to the U.S. dollar, and U.S. dollar intercompany receivables to the Australian dollar, which grew stronger relative to the U.S. dollar. These gains were offset by foreign currency losses in Argentina due to inflation during the period and hyperinflationary accounting.
During the three months ended June 30, 2019, the foreign currency losses were primarily recognized due to inflation in Argentina during the period and hyperinflationary accounting.
Income Taxes
Income tax expense was $0.6 million for the three months ended June 30, 2020 compared to income tax benefit of $6.3 million for the three months ended June 30, 2019. During the three months ended June 30, 2020, there were increases in valuation allowance positions related to the United States and certain foreign jurisdictions and the elimination of intercompany profit activity, offset by
30
foreign currency gains and foreign provision to return tax benefits, primarily in France. For the three months ended June 30, 2019, the elimination of intercompany profits resulted in a smaller income tax benefit.
Comparison of Results of Operations for the six months ended June 30, 2020 compared to the six months ended June 30, 2019.
Net Sales
Net sales were $53.0 million for the six months ended June 30, 2020, as compared to net sales of $60.1 million for the six months ended June 30, 2019, a decrease of 11.8%. The impacts of the change in foreign currency rates reduced revenue by $3.8 million for the first half of 2020. Excluding this impact, revenue decreased approximately 5.5%. The net sales decrease on a constant currency basis was primarily the result of adverse harvest conditions experienced in key Southern hemisphere markets, such as Brazil, Chile, Argentina and Australia which impacted harvest timing and yields, along with change in demand patterns from customers.
Cost of Sales
Cost of sales was $15.0 million for the six months ended June 30, 2020 as compared to $17.6 million for the six months ended June 30, 2019. Gross profit margin was 71.7% for the six months ended June 30, 2020 versus 70.7% for the six months ended June 30, 2019. The higher gross margin was a result of supply chain cost optimizations that were implemented at the end of 2019 and are expected to carry through the balance of 2020.
Research and Development Expenses
Research and development expenses were $5.5 million and $7.2 million, respectively, for the six months ended June 30, 2020 and June 30, 2019. The decrease in research and development expenses in the first half of 2020 was partially driven by the timing of projects.
Selling, General and Administrative Expenses
Selling, general and administrative expenses were $26.4 million for the six months ended June 30, 2020 compared to $32.0 million for the six months ended June 30, 2019, a decrease of 17.5%. There were non-recurring costs associated with M&A, litigation, refinancing and severance in the amount of $2.5 million in the current year and $5.2 million in the prior year period. Excluding these items, selling general and administrative expenses decreased approximately 10.5% over the same period last year driven by ongoing cost optimization initiatives, and to a lesser extent reflect the temporary decrease in travel and other miscellaneous expenses as a result of the global pandemic.
Amortization of Intangibles
Amortization of intangible assets was $21.9 million for the six months ended June 30, 2020 compared to $23.4 million for the six months ended June 30, 2019. The reduction in the amortization expense for the six months ended June 30, 2020 is due to the accelerated amortization of RipeLock in December 2019 of $38.0 million, which resulted in lower amortization of $1.2 million during the period.
Impairment of Intangibles
There were no indicators of impairment during the six months ended June 30, 2020. The Company recorded an impairment charge of $1.0 million during the six months ended June 30, 2019 associated with the Verigo software following a partnership agreement with a new technology provider.
Change in Fair Value of Contingent Consideration
The Company recorded no gain or loss for the six months ended June 30, 2020 related to a change in the fair value of contingent consideration, as compared to a $0.4 million loss in the six months ended June 30, 2019. As discussed in Note 3 - Business Combinations and Asset Acquisition of the unaudited condensed consolidated financial statements, pursuant to the Business Combination the Company entered into various forms of contingent consideration, including the tax amortization benefit contingency. These liabilities are measured at fair value each reporting date and any mark-to-market fluctuations are recognized in earnings. In December 2019, the TRA with Dow was terminated, and the Company paid to Dow an aggregate of $16 million in
31
settlement of all past and estimated future liabilities that would have been owed under the TRA. The fair value adjustment of the contingent consideration related to the Tecnidex acquisition was settled in 2019.
Grant Income
The Company recorded income of $3.0 million in the six months ended June 30, 2020. Pursuant to the CARES Act, the Company received a Paycheck Protection Program loan to offset eligible costs incurred during the period. As the Company believes it is in compliance with the forgiveness criteria under this loan program, the full amount was recognized as grant income.
Other Income
Other income was $1.5 million for the six months ended June 30, 2020, as compared to $0.04 million expense for the six months ended June 30, 2019. The Company received $1.6 million in cash from settlement of a litigation matter during the six months ended June 30, 2020.
Interest Expense, Net
Interest expense was $13.5 million for the six months ended June 30, 2020, as compared to $17.4 million for the six months ended June 30, 2019. The decrease was primarily due to $3.0 million lower interest on the Term Loan (as defined below) due to a lower variable rate and $1.7 million lower accretion on the TRA due to the settlement of the TRA in December 2019.
Gain (Loss) on Foreign Currency
Gain on foreign currency was $1.1 million for the six months ended June 30, 2020, as compared to a loss of $2.9 million for the six months ended June 30, 2019.
During 2020, foreign currency gains were recognized related to the U.S. dollar and euro intercompany payables to Turkish lira, South African rand and Brazilian real, which experienced inflation during the period, offset by foreign currency losses in Argentina due to inflation during the period and hyperinflationary accounting. During 2019, the loss was primarily related to foreign currency losses in Argentina due to inflation during the period and hyperinflationary accounting.
Income Taxes
Income tax benefit was $3.2 million for the six months ended June 30, 2020 compared to income tax benefit of $6.9 million for the six months ended June 30, 2019. During the six months ended June 30, 2020, there were changes in valuation allowance positions related to certain foreign jurisdictions and foreign exchange currency gains, offset by foreign provision to return tax benefits, predominantly in France. For the six months ended June 30, 2020, the changes in valuation allowance positions related to the Unites States interest expense disallowance carryforwards decreased the tax benefit, but because of the larger pre-tax book losses in 2019, the overall tax benefit was larger in 2019 than 2020.
32
Non-GAAP Measures
The following table sets forth the non-GAAP financial measures of EBITDA and Adjusted EBITDA. The Company believes these non-GAAP financial measures provide meaningful supplemental information as they are used by the Company’s management to evaluate the Company’s performance (including incentive bonuses and for bank covenant reporting), are more indicative of future operating performance of the Company, and facilitate a better comparison among fiscal periods. These non-GAAP results are presented for supplemental informational purposes only and should not be considered a substitute for the financial information presented in accordance with GAAP.
The following is a reconciliation between the non-GAAP financial measures of EBITDA and Adjusted EBITDA to their most directly comparable GAAP financial measure, net loss:
(in thousands) | Three Months Ended June 30, 2020 | Three Months Ended June 30, 2019 | Six Months Ended June 30, 2020 | Six Months Ended June 30, 2019 | ||||||||||
GAAP net loss including non-controlling interests | $ | (16,751) | $ | (22,361) | $ | (20,565) | $ | (34,946) | ||||||
Expense (benefit) for income taxes | 630 | (6,290) | (3,201) | (6,877) | ||||||||||
Interest expense (1) | 6,513 | 8,670 | 13,479 | 17,415 | ||||||||||
Depreciation and amortization | 11,568 | 12,275 | 23,145 | 24,336 | ||||||||||
Non-GAAP EBITDA | $ | 1,960 | $ | (7,706) | $ | 12,858 | $ | (72) | ||||||
Share-based compensation | 974 | 595 | 1,762 | 1,152 | ||||||||||
Severance related costs (2) | 74 | 207 | 74 | 696 | ||||||||||
Other non-recurring costs (3) | 639 | 1,815 | 2,383 | 5,008 | ||||||||||
(Gain) loss on foreign currency exchange (4) | (449) | 2,519 | (1,076) | 2,938 | ||||||||||
Mark-to-market adjustments, net (5) | — | 167 | — | 357 | ||||||||||
Impairment of intangible assets (6) | — | 992 | — | 992 | ||||||||||
Grant income | (2,974) | — | (2,974) | — | ||||||||||
Litigation recovery | — | — | (1,600) | — | ||||||||||
Non-GAAP Adjusted EBITDA | $ | 224 | $ | (1,411) | $ | 11,427 | $ | 11,071 |
(1) Interest on the term loan and accretion for debt discounts, debt issuance costs and contingent consideration.
(2) Severance costs related to ongoing cost optimization initiatives.
(3) Costs related to certain professional and other infrequent or non-recurring fees, including those associated with litigation and M&A related fees.
(4) (Gain) loss on foreign currency exchange relates to net losses and gains resulting from transactions denominated in a currency other than the entity's functional currency.
(5) Non-cash adjustment to the fair value of contingent consideration related to the Tecnidex acquisition.
(6) Impairment of intangible assets related to software.
The following is a reconciliation between net sales on a non-GAAP constant currency basis to GAAP net sales:
(in thousands) | Three Months Ended June 30, 2020 | Three Months Ended June 30, 2019 | Six Months Ended June 30, 2020 | Six Months Ended June 30, 2019 | ||||||||||
GAAP net sales | $ | 19,982 | $ | 21,183 | $ | 53,005 | $ | 60,123 | ||||||
Impact from changes in foreign currency exchange rates | 1,719 | — | 3,801 | — | ||||||||||
Non-GAAP constant currency net sales (1) | $ | 21,701 | $ | 21,183 | $ | 56,806 | $ | 60,123 |
(1) The company provides net sales on a constant currency basis to enhance investors’ understanding of underlying business trends and operating performance, by removing the impact of foreign currency exchange rate fluctuations. The impact from foreign currency, calculated on a constant currency basis, is determined by applying prior period average exchange rates to current year results.
33
Liquidity and Capital Resources
Cash Flow
(in thousands) | Six Months Ended June 30, 2020 | Six Months Ended June 30, 2019 | ||||||
Net cash provided by operating activities | $ | 9,155 | $ | 6,127 | ||||
Net cash used in investing activities | $ | (905) | $ | (3,519) | ||||
Net cash used in financing activities | $ | (1,091) | $ | (2,805) |
Cash provided from operating activities was $9.2 million for the six months ended June 30, 2020, as compared to cash provided from operating activities of $6.1 million for the six months ended June 30, 2019. In 2020, net income before non-cash depreciation and amortization was $2.6 million. Other non-cash charges included stock-based compensation of $1.6 million, $1.2 million of deferred financing costs, a $(5.7) million increase in net deferred taxes and interest income recognized on the interest rate swap of $(0.7) million. Additionally, the change in net operating assets was $10.1 million in 2020. For the six months ended June 30, 2019, net loss before non-cash depreciation and amortization and changes in fair value of contingent consideration (including accretion) was $(7.5) million. Other non-cash charges included interest income recognized on the interest rate swap of $(0.7) million, stock-based compensation of $1.4 million, $1.4 million of deferred financing costs, a $(8.2) million increase in net deferred tax assets and other non-cash items of $0.3 million. Additionally, the change in net operating assets was $19.3 million for the six months ended June 30, 2019.
Cash used in investing activities was $(0.9) million for the six months ended June 30, 2020, as compared to $(3.5) million for the six months ended June 30, 2019. Cash used in investing activities in 2020 was for the purchase of fixed assets and leasehold improvements of $(0.9) million. Cash used in 2019 was for the purchase of fixed assets and leasehold improvements of $(3.3) million and other investments of $(0.3) million.
Cash used in financing activities was $(1.1) million for the six months ended June 30, 2020, as compared to $(2.8) million for the six months ended June 30, 2019. Cash used in financing activities in 2020 was for the repayment of debt in the amount of $(2.7) million, offset by long-term borrowings of $1.4 million and proceeds from the issuance of stock of $0.2 million. Cash used in 2019 was for the repayment of debt in the amount of $(2.8) million.
Liquidity
At June 30, 2020, we had $35.6 million of cash and cash equivalents, compared to $29.3 million at December 31, 2019.
Term Loan
On July 31, 2015, certain of our subsidiaries entered into a Credit Agreement with Bank of Montreal, as administrative agent (as amended, the “Credit Facility”). The Credit Facility consists of a $425 million term loan (the “Term Loan”), with an amortization equal to 1.00% per year, and a revolving loan facility (the “Revolving Loan”). The Revolving Loan includes a $10 million letter-of-credit sub-facility, issuances against which reduce the available capacity for borrowing. As of December 31, 2019, the Company has issued $0.03 million of letters of credit, against which no funds have been drawn. The Term Loan has a scheduled maturity date of July 31, 2021, and the Revolving Loan, as amended on December 23, 2019, has a scheduled maturity date of April 1, 2021. The interest rates on borrowings under the facilities are either the alternate base rate plus 3.75%, or LIBOR plus 4.75% per annum, with a 1.00% LIBOR floor (with step-downs in respect of borrowings under the Revolving Loan dependent upon the achievement of certain financial ratios). The obligations under the Credit Facility are secured by liens on substantially all of the assets of (a) AgroFresh Inc. and its direct wholly-owned domestic subsidiaries, and (b) AF Solutions Holdings LLC, including the common stock of AgroFresh Inc.
The net proceeds of the Term Loan were used to fund a portion of the purchase price payable to Dow in connection with the Business Combination. Amounts available under the Revolving Loan may also be used for working capital, general corporate purposes and other uses, all as more fully set forth in the Credit Facility.
As of June 30, 2020, the Company was in compliance with the covenants in the facility, other than covenants that apply only to the Company's ability to borrow under the Revolving Loan (excluding letters of credit). On January 31, 2019, the Credit Facility was amended to decrease the total availability from $25.0 million to $12.5 million and extend the maturity of the Revolving Loan from July 31, 2019 to December 31, 2020. An existing covenant in the Credit Agreement was also amended to allow the Company to have access to the Revolving Loan. Subsequently, on December 23, 2019, the Revolving Loan was further amended to extend the maturity to April 1, 2021 and included favorable revisions to the senior secured net leverage ratio covenant.
34
As of the Closing Date the Company incurred approximately $12.9 million in debt issuance costs related to the Term Loan and $1.3 million in costs related to the Revolving Loan. The debt issuance costs associated with the Term Loan were capitalized against the principal balance of the debt, and the Revolving Loan costs were capitalized in Other Assets. All issuance costs will be accreted through interest expense for the duration of each respective debt facility. The interest expense related to the amortization of the debt issuance costs during the three months ended June 30, 2020 and 2019, was approximately $0.6 million and $0.6 million, respectively. The interest expense related to the amortization of the debt issuance costs during the six months ended June 30, 2020 and 2019 was approximately $1.2 million and $1.1 million, respectively.
On July 27, 2020, the Company (i) consummated the sale to PSP AGFS Holdings, L.P. (the “Investor”) of 150,000 shares of the Company’s newly-designated Series B-1 Convertible Preferred Stock (the “Series B-1 Preferred Stock”) for an aggregate gross purchase price of $150,000,000, less a one-time transaction fee equal to $4,500,000, pursuant to the terms of the Investment Agreement, dated June 13, 2020, between the Company and the Investor (the “Investment Agreement”), and (ii) entered into an Amended and Restated Credit Agreement, which amended and restated the Credit Facility in its entirety and extended the maturity date. Refer to Note 22, Subsequent Events, of the Notes to the Unaudited Condensed Consolidated Financial Statements and Item 5 of Part II of this report for additional information.
Off-Balance Sheet Arrangements
As of June 30, 2020, the Company did not have any off-balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K and did not have any commitments or contractual obligations other than as disclosed in Note 20 of the unaudited condensed consolidated financial statements. The Company has not guaranteed any debt or commitments of other entities or entered into any options on non-financial assets.
35
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
As a smaller reporting company, we are not required to provide the information required by this Item.
ITEM 4. CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
An evaluation was carried out under the supervision and with the participation of our management, including our Chief Executive Officer and our Chief Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Based on the evaluation of our disclosure controls and procedures, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures were effective to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act was recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information required to be disclosed is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.
Changes in Internal Controls
There were no changes in the Company's internal control over financial reporting that occurred during the Company's most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.
36
PART II- OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
From time to time we are named as a defendant in legal actions arising from our normal business activities. Although we cannot predict with certainty the ultimate resolution of lawsuits, investigations and claims asserted against us, we do not believe any currently pending legal proceeding to which we are a party will have a material adverse effect on our business, prospects, financial condition, cash flows or results of operations.
In July 2020, three separate putative class action lawsuits were filed against the Company, each alleging that the Company’s disclosures regarding the transactions contemplated by the Investment Agreement contained in its proxy statement for the 2020 annual meeting of the Company’s stockholders were inadequate.
ITEM 1A. RISK FACTORS
Ownership of our securities involves a high degree of risk. Holders of our securities should carefully consider, in addition to the historical financial statements and related notes and other information set forth in this Report, the risk factors discussed in Part I - Item 1A - Risk Factors included in our 2019 Form 10-K, all of which could materially affect our business or future results. Other than the amended and restated risk factors and the additional risk factors set forth below, we are not currently aware of any material changes to the risk factors disclosed in our 2019 Form 10-K. If any of the risks or uncertainties described in any of such risk factors actually occur, our business, financial condition and operating results could be adversely affected in a material way. This could cause the trading prices of our securities to decline, perhaps significantly, and you may lose part or all of your investment.
The Investor and The Dow Chemical Company (“Dow”) have significant influence over us, which could limit your ability to influence the outcome of key transactions, including a change of control.
As of July 31, 2020, the Investor owned 150,000 shares of our Series B-1 preferred stock (the “Series B-1 Preferred Stock”), which is currently convertible into approximately 10.4 million shares of our outstanding common stock (and which votes with our common stock on an as-converted basis), and Dow owned approximately 21 million shares of our outstanding common stock. In addition, following the approval of the transactions contemplated by the Investment Agreement by the Australian Foreign Investment Review Board, the shares of Series B-1 Preferred Stock will be exchanged for shares of our newly-designated Series B Preferred Stock (the “Series B Preferred Stock” and, together with the Series B-1 Preferred Stock, the “Preferred Stock”), which would initially be convertible into approximately 36% of our outstanding common stock (and which will vote with our common stock on an as-converted basis). In addition, we will issue additional shares of Preferred Stock to the Investor as dividends payable-in-kind on the Preferred Stock. Because of the degree of concentration of voting power (and the potential for such power to increase upon the purchase of additional stock and/or the payment of dividends-in-kind), your ability to elect members of our board of directors and influence our business and affairs, including any determinations with respect to mergers or other business combinations, the acquisition or disposition of assets, the incurrence of indebtedness, the issuance of any additional common stock or other equity securities, the repurchase or redemption of common stock and the payment of dividends, may be diminished.
In addition, the Investor and Dow have representation on the Company’s board of directors and have significant control over the management and affairs of the Company. The Investor currently has two designees on the board of directors, and commencing on July 27, 2021 (or earlier under certain circumstances) will have the right to appoint additional directors to the board, such that the total number of its designees would be proportionate to its ownership of common stock, on an as-converted basis. Dow (or an affiliate) has one designee on the board of directors and would have the right to appoint an additional director in the future under certain circumstances. The Investor also has class approval rights over certain specified actions that would affect the holders of the Preferred Stock, and following the issuance of the Series B Preferred Stock will have the right to approve certain corporate actions for so long as it continues to hold at least 10% of the shares of common stock outstanding (on an as-converted basis).
Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
As of December 31, 2019, we had aggregate U.S. net operating loss carryforwards of approximately $102.6 million, These net operating loss carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under the Tax Cuts and Jobs Act, federal net operating losses incurred in taxable years ending after December 31, 2017 may be carried forward indefinitely, but the deductibility of federal net operating losses generated in tax years beginning after December 31, 2017 is limited. It is uncertain if and to what extent various states will conform to the Tax Cuts and Jobs Act. In addition, under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, and corresponding provisions of state law, if a corporation undergoes an “ownership change” (which is generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period), the corporation’s ability to use its pre-change net operating loss carryforwards and other pre-change tax
37
attributes to offset its post-change income or taxes may be limited. We experienced an ownership change as a result of the consummation of the sale of the Preferred Stock to the Investor. Such ownership change may materially limit our ability to use our net operating loss carryforwards, which may harm our future operating results by effectively increasing our future tax obligations. The Company is in the process of determining the limitation and related impact on the use of its net operating losses.
Risks associated with the current uncertainty with respect to rapid expansion of the COVID-19 pandemic
We are cognizant of the rapid expansion of the COVID-19 pandemic and the resulting global implications. To date, we have been able to manage our day-to-day operations without significant disruptions. However, there continues to be a possibility for potential developments that could adversely affect our operations, research and development and marketing plans. The impact of these restrictions on the results of our business, if implemented, is currently unknown but could be significant.
38
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Not applicable.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
Not applicable.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
Not applicable.
39
ITEM 6. EXHIBITS
Exhibit No. | Description | |||||||||||||
(7) | ATM Sales Agreement, dated June 25, 2020, between AgroFresh Solutions, Inc. and Virtu Americas LLC. | |||||||||||||
(1) | Second Amended and Restated Certificate of Incorporation, filed with the Secretary of State of the State of Delaware on July 31, 2015. | |||||||||||||
(4) | Certificate of Amendment to the Second Amended and Restated Certificate of Incorporation. | |||||||||||||
(1) | Series A Certificate of Designation. | |||||||||||||
(2) | Amended and Restated Bylaws. | |||||||||||||
(3) | Amendment to the Amended and Restated Bylaws of AgroFresh Solutions, Inc., effective as of September 3, 2015. | |||||||||||||
(5) | Amendment to the Amended and Restated Bylaws of AgroFresh Solutions, Inc., effective as of November 2, 2017. | |||||||||||||
(1) | Specimen Common Stock Certificate. | |||||||||||||
(1) | Specimen Warrant Certificate. | |||||||||||||
(6) | Investment Agreement, dated June 13, 2020, between the Company and PSP AGFS Holdings, L.P. | |||||||||||||
(6) | Side Agreement, dated June 13, 2020, between the Company, PSP AGFS Holdings, L.P. and Rohm & Haas Company. | |||||||||||||
* | Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended. | |||||||||||||
* | Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Act of 1934, as amended. | |||||||||||||
* | Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |||||||||||||
101.INS | * | XBRL Instance Document | ||||||||||||
101.SCH | * | XBRL Taxonomy Extension Schema Document | ||||||||||||
101.CAL | * | XBRL Taxonomy Extension Calculation Linkbase Document | ||||||||||||
101.DEF | * | XBRL Taxonomy Extension Definition Linkbase Document | ||||||||||||
101.LAB | * | XBRL Taxonomy Extension Label Linkbase Document | ||||||||||||
101.PRE | * | XBRL Taxonomy Extension Presentation Linkbase Document |
———————————————————————————————
* Filed herewith.
(1) Incorporated by reference to an exhibit to the Current Report on Form 8-K of the Company filed with the Securities and Exchange Commission on August 6, 2015.
(2) Incorporated by reference to Annex A to the Company’s definitive proxy statement (File No. 001-36197) filed with the Securities and Exchange Commission on July 16, 2015.
(3) Incorporated by reference to an exhibit to the Current Report on Form 8-K of the Company filed with the Securities and Exchange Commission on September 10, 2015.
(4) Incorporated by reference to an exhibit to the Current Report on Form 8-K of the Company filed with the Securities and Exchange Commission on June 7, 2017.
(5) Incorporated by reference to an exhibit to the Quarterly Report on Form 10-Q of the Company filed with the Securities and Exchange Commission on November 9, 2017.
(6) Incorporated by reference to an exhibit to the Current Report on Form 8-K of the Company filed with the Securities and Exchange Commission on June 15, 2020.
(7) Incorporated by reference to an exhibit to the Current Report on Form 8-K of the Company filed with the Securities and Exchange Commission on June 26, 2020.
40
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
AgroFresh Solutions, Inc. | ||||||||
Date: | August 10, 2020 | |||||||
/s/ Jordi Ferre | ||||||||
By: | Jordi Ferre | |||||||
Title: | Chief Executive Officer | |||||||
/s/ Graham Miao | ||||||||
By: | Graham Miao | |||||||
Title: | Chief Financial Officer |
41